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Abstract 
 
Introduction: Obesity and its associated complications, such as the 
metabolic syndrome, hypertension and cardiovascular disease, are escalating 
worldwide. In recognition of this, untested remedies advertised as anti-diabetic 
agents are flooding the market. Many of these products have limited efficacy, 
limited tolerability and significant side-effects. One remedy, claiming to have 
anti-diabetic properties, is DiaviteTM. DiaviteTM, a herbal product, consisting 
solely of the dried and ground pods of the Prosopis glandulosa tree, which is 
currently marketed as a food supplement with blood glucose and blood 
pressure stabilizing properties, as well as having the ability to enhance 
glucose utilization.  It is already freely available from agents as well as sold 
over the counter at pharmacies. The producers of DiaviteTM are now seeking 
registration for their product from the Medicines Control Council (MCC) and, 
therefore, require solid scientific evidence of its effects.  
Aims: The aims of our study were, on request of the producing company, to 
determine the efficacy of DiaviteTM (P. glandulosa) as an anti-diabetic agent 
and possible mechanisms of action of this plant product.   
Methology: We utilized rat models of streptozotocin (STZ)-induced type 1 
diabetes and diet-induced obese (DIO) insulin resistance. Male Wistar rats 
were rendered (a) type 1 diabetic after a once-off intra-peritoneal injection of 
STZ at a dose of 40 mg/kg and (b) insulin resistant after being on a high 
caloric diet (DIO) for 16 weeks. Half the animals of the type 1 diabetes model 
as well as the insulin resistant model were placed on DiaviteTM treatment (25 
mg/kg/day) for a period of 4 – 8 weeks, depending on the model.  The STZ-
induced type 1 diabetic rats were sacrificed and the pancreata harvested for 
histological analysis. Animals on the DIO diet were sacrificed and (i) intra-
peritoneal fat weight determined (ii) isolated hearts subjected to 
ischaemia/reperfusion to determine infarct size and protein expression profiles 
and (iii) cardiomyocytes prepared to determine insulin sensitivity. At the time 
of sacrifice blood was collected for blood glucose and serum insulin level 
 iii
determination, for both models. In addition, a standard toxicology study was 
performed in Vervet monkeys over a 3 month period. 
Results: In our type 1 diabetic model (blood glucose > 10 mmol/L) with a β-
cell reserve, DiaviteTM treatment lead to increased serum insulin levels (p < 
0.001) in both control and STZ groups as well as increased small β-cell (0 - 
2500 µm2) formation (p < 0.001) in the pancreas of the STZ animals. Hearts 
from DiaviteTM treated control and DIO insulin resistant animals presented 
with smaller infarct sizes (p < 0.05) after ischaemia/reperfusion compared to 
their controls. DiaviteTM treatment lead to the increase of basal (p < 0.01) and 
insulin-stimulated (p < 0.05) glucose uptake in cardiomyocytes prepared from 
DIO insulin resistant animals. DiaviteTM treatment also led to significantly 
suppressed PTEN expression and activity (p < 0.01) in the DIO insulin 
resistant animals. In addition, DiaviteTM treatment had (i) no obvious 
detrimental effects in our rat models and (ii) no toxicity over a 3 month period 
in vervet monkeys. 
Conclusion: Our present study has shown that DiaviteTM treatment lowers 
fasting blood glucose levels, stimulates insulin secretion and leads to the 
formation of β-cells. In addition, oral consumption of DiaviteTM elicits 
cardioprotection against an ischaemic incident. DiaviteTM treatment improves 
insulin sensitivity of cardiomyocytes. Furthermore, it has been established that 
DiaviteTM treatment has no obvious detrimental effects in either of our rat 
models and no short-term toxic effects over a 3 month period in Vervet 
monkeys (data not shown). 
We thus conclude that in our models, DiaviteTM proved safe and it seems as if 
DiaviteTM, after short-term use, is beneficial as a dietary supplement.  
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Opsomming 
 
Inleiding: Vetsug, en die gepaardgaande komplikasies, soos die metaboliese 
sindroom, hipertensie en kardiovaskulêre siektes, neem wêreldwyd toe. Daar 
is tans verskeie middels op die mark wat as anti-diabetiese middels 
geadverteer word. Baie van hierdie geadverteerde produkte het beperkte 
effektiwiteit en het verskeie newe-effekte. Een so ‘n middel, is DiaviteTM.  
DiaviteTM is 'n plantproduk, wat slegs uit die gedroogte en fyngemaakte peule 
van die P. glandulosa boom bestaan. Hierdie produk word tans bemark as 'n 
voedselaanvulling met beide bloedglukose en bloeddruk stabiliserende 
eienskappe, asook die vermoë om glukose gebruik te verbeter. DiaviteTM is 
reeds vrylik beskikbaar van agente sowel as verkrygbaar by verskeie apteke. 
Die produsente van DiaviteTM wil aansoek doen om registrasie vir hul produk 
by die Medisynebeheerraad (MCC) en hulle vereis daarom wetenskaplike 
bewyse van die gevolge van die gebruik van hierdie produk.  
 Doel: Die doel van ons studie was om op versoek van die produksie 
maatskappy, die doeltreffendheid van DiaviteTM (P. glandulosa) as 'n anti-
diabetiese behandeling te evalueer, sowel as die moontlike meganismes van 
werking van hierdie plantproduk.  
Metodes: Ons het gebruik gemaak van rot modelle van (i) streptozotocin 
(STZ)-geïnduseerde tipe 1 diabetes en (ii) dieet-geïnduseerde vetsugtig (DIO) 
insulienweerstandigheid. Manlike Wistar rotte was as (a) tipe 1 diabeties 
geklassifiseer na 'n eenmalige, intra-peritoneale inspuiting van STZ teen 'n 
dosis van 40 mg/kg en as (b) insulienweerstandig geklassifiseer, nadat hulle 
op 'n hoë kalorie dieet (DIO) vir 16 weke was.  Die helfte van beide die tipe 1 
diabetes en die insulienweerstandige groep diere was met DiaviteTM behandel 
(25 mg/kg/dag) vir 'n tydperk van 4 - 8 weke, afhangende van die model.  Die 
STZ-geïnduseerde tipe 1 diabetes rotte is geslag en die pankreata geoes vir 
histologiese analise. Diere op die DIO dieet is geslag en (i) die intra-
peritoneale vet gewig bepaal, (ii) die geïsoleerde harte blootgestel aan 
isgemie/herperfusie om die infarkt groottes vas te stel, sowel as die 
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proteïenuitdrukkingsprofiele te bepaal en (iii) kardiomiosiete was berei om die 
insulien sensitiwiteit te bepaal.  Ten tyde van die slagting is bloedmonsters 
geneem vir bloedglukose en serum insulien vlak bepaling, vir beide modelle.  
Additioneel, is 'n standaard toksologie studie met Vervet apies oor 'n 3 
maande tydperk uitgevoer.  
Resultate: In die model van tipe 1 diabetes (bloed glukose > 10 mmol/L), met 
'n β-sel reserwe, is gevind dat DiaviteTM behandeling tot verhoogde serum 
insulien vlakke (p < 0.001) in beide kontrole en STZ groepe lei.  DiaviteTM 
behandeling lei ook tot ‘n hoër vlak van klein β-sel (0 - 2500 µm2) vorming (p < 
0.001) in die pankreas van die STZ diere.  Die harte van die DiaviteTM 
behandele kontrole en DIO groep het kleiner infarkt groottes (p < 0.05) getoon 
na isgemie/herperfusie in vergelyking met hul kontrole groepe. DiaviteTM 
behandeling het ook gelei tot verhoogde basal (p < 0. 01) en insulin-
gestimuleerde (p < 0. 05) glukose opname in kardiomiosiete wat berei was 
van DIO insulinweerstandige diere. DiaviteTM behandeling het PTEN 
uitdrukking en aktiwiteit aansienlik onderdruk (p < 0.01) in die DIO 
insulienweerstandige groep diere. Daar is dus gevind dat DiaviteTM 
behandeling (i) geen duidelike nadelige invloed in ons rot-modelle en (ii) geen 
toksisiteit oor 'n 3 maande tydperk in Vervet apies getoon nie.  
Gevolgtrekking: Ons huidige studie toon dus dat DiaviteTM behandeling 
vastende bloedglukosevlakke verlaag, insulien sekresie stimuleer en die 
proses van β-sell vorming bevorder.  Additioneel, is gewys dat wanneer 
DiaviteTM mondelings gebruik word, dit die hart beskerm teen isgemiese 
insidente.  Ons het ook getoon dat DiaviteTM behandeling insuliensensitiwiteit 
van kardiomiosiete verhoog.  Verder is daar vasgestel dat DiaviteTM 
behandeling geen ooglopende nadelige gevolge in beide ons rot-modelle 
getoon het nie en daar geen korttermyn-toksiese effekte oor 'n 3 maande 
tydperk in Vervet apies (data nie getoon) is nie.  
Ons kan dus aflei dat Diavite TM in ons modelle veilig is en na kort termyn 
gebruik, voordelig is as 'n dieetaanvulling.  
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Motivation for research 
 
Being overweight or obese has severe health consequences. The increased 
incidence of insulin resistance and type 2 diabetes, of which a high 
percentage can be directly attributed to weight gain [Stein and Colditz, 2004; 
Eckel et al., 2005], is amongst the most devastating. Type 2 diabetes is a 
disease of serious concern, due to its associated complications and the 
enormous impact it has on health care costs. In recognition of this, the need 
for therapeutics is crucial and normalizing blood glucose levels and improving 
insulin sensitivity needs to be the primary targets of therapies.  
With this in mind, untested remedies advertised as anti-diabetic agents are 
flooding the market. Many of these advertised products have limited efficacy, 
limited tolerability and significant side-effects and few of the available products 
adequately address the underlying defects associated with diabetes, such as 
obesity and/or insulin resistance. One such remedy, claiming to have anti-
diabetic properties, is DiaviteTM. DiaviteTM, marked by a South African 
company by the name of Conbrio Brands (Pty) Ltd, is a herbal product that is 
currently marketed as a food supplement with blood glucose and blood 
pressure stabilizing properties as well as having the ability to improve glucose 
homeostasis.  It is already freely available from agents as well as sold over 
the counter at pharmacies at a recommended dose of 7g daily. The producers 
of DiaviteTM are, however, now seeking registration for their product from the 
Medicines Control Council (MCC) and therefore require solid scientific 
evidence of its effects. 
DiaviteTM consists solely of the dried and ground pods of the P. glandulosa 
tree (more commonly known as the Honey mesquite tree) which is part of the 
Fabaceae (or legume) family. In the past, the pods of this tree were used as 
the primary foodstuff for the residents of the south-western regions of the 
North American deserts [Simpson, 1977] and these trees are still widely 
distributed across a large portion of the south-western United States 
[Washburn et al., 2002].  
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Grinding of the plant is thought to improve its use as animal feed. It has, 
however, been found that the ingestion of the young leaves, pods or beans of 
the P. glandulosa can cause toxicosis if it comprises the majority of the diet of 
the animals [Washburn et al., 2002]. It appears that sheep are more resistant 
to the plant’s toxic effects and they are thus able to consume a higher 
percentage of the young leaves, pods and/or beans in their diet than are cattle 
and goats [Washburn et al., 2002]. The clinical signs of the toxic effects of this 
plant in animal models include weight loss, ptyalism (drooling), mandibular 
tremors, tongue protrusion, dysphagia (difficulty in swallowing) and episodes 
of hypoglycaemia [Washburn et al., 2002]. 
In South Africa, it was once one of the most common trees found in the dry 
north-western regions. Beginning in the 1880’s numerous Prosopis species, 
including P. glandulosa, were introduced to South Africa from various sources 
in the Americas and became a common ornamental tree in many towns. For 
many years it was perceived to be a valuable source of shade, animal feed 
and fuel wood and this was the main reasons that Prosopis was introduced 
from the Americas to many parts of the world. However, in the 1960’s this 
perception changed when the first alarming infestations appeared. During this 
time, hybridization between two dominant Prosopis species namely, P. 
velutina and P. glandulosa, started to occur and displayed what is known as 
“hybrid vigour”. These hybrids proved to be very invasive and these hybrid 
trees lost most of their valuable properties [Steenkamp and Chown, 1996]. In 
1983, P. velutina and P. glandulosa (including their hybrids), where declared 
category 2 invaders under the Conservation of Agricultural Resources Act of 
1983 (Act No. 43 of 1983) (CARA) [Steenkamp and Chown, 1996]. Category 2 
invader plants are plants with the proven potential of becoming invasive, but 
which nevertheless have certain beneficial properties that warrant their 
continued presence in certain circumstances. By demarcating and controlling 
the area in which these trees grow according to set regulations, producers can 
benefit from its resources.   
In a pilot study conducted in 2006, we found that genetically type 2 diabetic 
rats, (Zucker fa/fa) treated with DiaviteTM, had decreased fasting glucose 
 xxii
levels and an improved intraperitoneal glucose tolerance test (IPGTT) in 
comparison to untreated controls. In addition to that, cardiomyocytes prepared 
from these rats, were more insulin sensitive after DiaviteTM treatment.  
Our aim was therefore, on request of the producing company, to determine the 
efficacy of DiaviteTM (P. glandulosa) as an anti-diabetic agent and possible 
mechanisms of action of this plant product in both type 1 and type 2 diabetic 
rats. We utilized rat models of streptozotocin-induced type 1 diabetes and diet-
induced obese (DIO) insulin resistance. 
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CHAPTER 1 
Literature review 
 
1. THE “PANDEMIC” OF OBESITY 
The prevalence of obesity has focused attention on a worldwide problem that 
is on a rampant increase. Obesity is a serious public health issue, escalating 
in countries with low and middle income [World Health Organization, 2006]. It 
has been estimated that there are approximately 1.1 billion overweight (body 
mass index: BMI ≥ 25 kg/m2) adults worldwide and a further 312 million adults 
that are obese (BMI ≥ 30 kg/m2) [Hossain et al., 2007; Deitel, 2003] with South 
Africa also not being spared in this global increase [Puoane et al., 2002].  
Over the past decades, much research has gone into the pathophysiology of 
obesity and its associated complications. According to the National Heart Lung 
and Blood Institute (NHLBI), obesity is one of the leading causes of 
preventable deaths globally [National Heart Lung and Blood Institute, 1998]. 
This is due to the strong association between obesity and the risk of 
developing metabolic abnormalities such as insulin resistance, type 2 diabetes 
and hypertension. All of which is well-documented risk factors for the 
development of cardiovascular diseases [Stein and Colditz, 2004; Smith, 
2007; Eckel et al., 2005].  
The sections that follow will discuss the link between obesity and disease 
states, such as insulin resistance, type 2 diabetes and cardiovascular disease 
and why research into obesity and its associated complications and the need 
for therapies, are so important. 
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2. PHYSIOLOGICAL MECHANISMS OF INSULIN ACTION 
Before discussing the link between obesity and insulin resistance, it is 
appropriate to give a brief discussion on the physiological importance and the 
mechanisms of action of insulin under normal physiological conditions. 
 
2.1 Overview of insulin action 
All animals undergo a cycle of feeding and starvation. During periods of 
feeding, nutrients are stored in forms that can be used as energy sources 
during later periods of fasting. Insulin, which is a hormone produced by the β-
cells of the pancreas, regulates this process. In response to hyperglycaemia 
the β-cells secretes insulin, which in turn stimulates the uptake of glucose by 
peripheral insulin sensitive tissues.  
Glucose homeostasis is most affected by skeletal muscle, liver and adipose 
tissue. In skeletal muscle and liver, insulin stimulation is responsible for the 
synthesis of glycogen from glucose and it is responsible for the inhibition of 
glycogenolysis. In the liver, insulin reduces gluconeogenesis, which in turn 
prevents an influx of additional glucose into the circulation [Saltiel and Kahn, 
2001]. In adipose tissue, insulin action inhibits lipolysis and stimulates glucose 
uptake into the tissue. The cumulative effect of all these changes is to 
enhance glucose utilization, reduce circulating glucose levels and increase the 
conversion of glucose into glycogen or fat for storage [Opie, 1998; Kim et al., 
2006] and thus keep the homeostatic balance.  
Section 2.2 on page 3 describes the involvement of insulin in glucose uptake 
and storage and the proteins and mechanisms responsible for insulin signaling 
termination. It is important to note that, although the pathways described 
below are illustrated in a linear fashion, it should not be forgotten that each 
pathway could, under certain circumstances, activate others. 
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2.2 From insulin stimulation to glucose storage 
Circulating insulin reaches its target tissue, where it interacts with its 
associated receptor, the insulin receptor (IR) [Rosen, 1989; Ebina et al., 1985; 
Ullrich et al., 1985]. The IR belongs to a large subfamily of receptor tyrosine 
kinases [Patti and Kahn, 1998], consisting of two extracellular α- and two 
transmembrane β-subunits. This subfamily of receptors are disulphide-bonded 
proteins that function as allosteric enzymes, in which the binding of insulin to 
the α-subunit induces a rapid conformational change, resulting in the 
autophosphorylation of specific tyrosine residues of the intracellular region of 
the β-subunit through a transphosphorylation mechanism [Van Obberghen et 
al., 2001; Hubbard, 1997]. These residues are recognized by 
phosphotyrosine-binding (PTB) domains of adaptor proteins such as members 
of the insulin receptor-substrate (IRS) family [Saltiel and Kahn, 2001; Lizcano 
and Alessi, 2002]. Autophosphorylation results in the activation of the tyrosine 
kinase activity of the receptor [Lee et al., 1997]. The activated IR 
phosphorylates substrate proteins on tyrosine residues, where these 
phosphorylated tyrosine residues act as “docking sites” for downstream 
effectors that contain Src homology 2 (SH2) domains. Many of these SH2-
containing proteins are adaptor molecules, such as the p85 regulatory subunit 
of phosphoinositide 3-kinases (PI3K). The metabolic response to insulin is 
primarily mediated via the PI3K/PKB/Akt pathway, which is a main prosurvival 
pathway. The catalytic subunit of PI3K, p110, then phosphorylates 
phosphatidylinositol (4,5) bisphosphate (or Ptdlns(4,5)P2, abbreviated as PIP2) 
leading to the formation of phosphorylated phosphatidylinositol (3,4,5) 
triphosphate (or Ptdlns(3,4,5)P3, abbreviated as PIP3). This process markedly 
stimulates the activation of serine kinase Akt (also known as protein kinase B, 
abbreviated as PKB or PKB/Akt) which is recruited to the plasma membrane. 
This incident predominantly relies on the phosphorylation of PKB/Akt at the 
Thr308 and Ser473 sites, by phosphoinositide-dependent kinase 1 (PDK-1) and 
mammalian target of rapamycin/rapamycin intensive companion of mTOR 
(mTOR/Rictor) complex respectively [Alessi et al., 1997; Hresko and 
Mueckler, 2005]. Once PKB/Akt has been activated, it enters the cytoplasm 
where it leads to the phosphorylation and inactivation of glycogen synthase 
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kinase 3 (GSK-3). The inactivation of GSK-3, in turn, promotes glucose 
storage as glycogen. Figure 1.1 (page 6), is a simplified overview of insulin 
stimulated GLUT4 translocation and glucose uptake. 
 
2.3 From insulin stimulation to GLUT4 translocation 
Glucose transporter 1 (GLUT1) and glucose transporter 4 (GLUT4) are the 
two main glucose transporters present in cardiomyocytes [Abel, 2004]. 
GLUT4, which continuously cycles from intracellular stores to the plasma 
membrane, plays an important role in glucose homeostasis in both animals 
and humans. At basal levels, GLUT4 resides in intracellular, cytoplasmic 
vesicles, however, during insulin stimulation GLUT4 translocates to the 
plasma membrane where it transports postprandial glucose from the 
extracellular environment into cells [Huang and Czech, 2007; Wallberg-
Henriksson and Zierath, 2001]. Insulin is thus the hormone responsible for 
increasing glucose transport by increasing the rate of GLUT4-vesicle 
exocytosis and by slightly decreasing the rate of internalization [Pessin et al., 
1999].  
In conjunction with insulin stimulated translocation, increased work demand 
and ischaemia [Stanley et al., 1997 (a); Young et al., 1997] also lead to 
GLUT4 translocation. The translocation of GLUT4 takes place by means of 
both a PI3K-dependent pathway and a PI3K-independent pathway [Pessin et 
al., 1999; Lizcano and Alessi, 2002]. 
 
2.3.1 PI3K-dependent pathway 
Insulin-stimulated GLUT4 translocation from vesicular intracellular 
compartments to the cell surface is a multiple-step process that involves 
intracellular sorting, vesicular transport to the cell surface along cytoskeletal 
elements, docking, priming and fusion of the GLUT4 storage vesicles with the 
cell surface.  
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PKB/Akt, activated via PI3K, phosphorylates the downstream protein, Akt 
substrate of 160 kDa (AS160, originally known as TBC1D4) and TBC1D1 at 
Thr642 and Thr596, respectively [Kahn et al., 2002; Sano et al., 2007]. This 
enhances binding of the scaffolding protein 14-3-3 to these proteins, which is 
thought to inhibit Rab-GTPase-activating protein (GAP) activity towards 
particular Rab isoform(s). Inhibition of GAP promotes conversion of less active 
GDP-loaded Rab to more active GTP-loaded Rab [Sakamoto and Holman, 
2008]. The more active GTP-loaded Rab then allows GLUT4 storage vesicles 
to move to and fuse with the plasma membrane [Sano et al., 2007; Sakamoto 
and Holman, 2008] (refer to Figure 1.1). 
 
2.3.2 PI3K-independent pathway 
It has also been suggested that a second pathway, a PI3K-independent 
pathway occurs as a consequence of Cbl tyrosine phosphorylation [Ribon and 
Saltiel, 1997; Liu et al., 2003]. The protooncogene, Cbl and the adaptor 
protein c-Cbl-associated protein (CAP) [Ribon and Saltiel, 1997; Ribon et al., 
1998] are recruited to the IR by adaptor molecules containing PH and SH2 
domains [Liu et al., 2003]. Upon phosphorylation, the Cbl-CAP complex 
translocates to lipid raft domains in the plasma membrane. The 
phosphorylated Cbl then recruits the adaptor protein CrkII, which forms a 
constitutive complex with the Rho-family guanyl nucleotide-exchange protein, 
C3G, to the lipid raft [Chiang et al., 2001]. Once translocated, C3G comes into 
close proximity with the G protein TC10 [Chiang et al., 2001], which promotes 
GLUT4 translocation to the plasma membrane [Huang and Czech, 2007; 
Wallberg-Henriksson and Zierath 2001; Watson and Pessin, 2006; Bryant et 
al., 2002]. Once brought into the proximity of fusion machinery at the plasma 
membrane by the cytoskeleton, the GLUT4 vesicle can dock and 
subsequently fuse, exposing GLUT4 to the extracellular environment [Saltiel 
and Kahn, 2001] (refer to Figure 1.1). It is important to note that the 
cytoskeleton is crucial in maintaining glucose homeostasis as it is involved in 
the distribution of IRS [Clark et al., 2000; Chang et al., 2004], the translocation 
of GLUT4 to the membrane [Tsakiridis et al., 1994; Vollenweider et al., 1997; 
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Wang et al., 1998] and the internalization of the IR [Boura-Halfon et al., 2003; 
Shorten et al., 2007]. Thus, dysfunction of the cytoskeleton may lead to insulin 
resistance. 
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Figure 1.1: Simplified overview of insulin stimulated GLUT4 translocation and 
glucose uptake. The IR undergoes autophosphorylation and catalyses the 
phosphorylation of members of the IRS family. Upon tyrosine phosphorylation, IRS 
proteins interact with signaling molecules through their SH2 domains, resulting in 
activation of PI3K and downstream PIP3-dependent protein kinase, PDK-1. PDK-1 
phosphorylates and activates PKB/Akt, which enters the cytoplasm and leads to the 
phosphorylation and inactivation of GSK-3. Inactivated GSK-3 promotes glucose 
storage as glycogen. Activated PKB/Akt also phosphorylates downstream protein, 
AS160, which enhances binding of scaffolding protein 14-3-3. This binding inhibits 
GAP, promoting the conversion of active GDP-loaded Rab to active GTP-loaded Rab. 
This allows for GLUT4 vesicle translocation to the cell surface. These pathways act in 
a concerted fashion to coordinate the regulation of vesicle trafficking, protein synthesis 
and gene expression. Adapted from Saltiel and Kahn (2001) and Watson and Pessin, 
(2006). IRS: insulin receptor substrate; PI3K: phosphoinositide 3-kinase; PIP2: 
phosphatidylinositol (4,5) bisphosphate; PIP3: phosphatidylinositol (3,4,5) 
triphosphate; PTEN: phosphatase and tensin homolog deleted on chromosome 10; 
PDK-1: phosphoinositide-dependent kinase 1; PKB/Akt: protein kinase B; GSK-3: 
glycogen synthase kinase 3; GLUT4: glucose transporter 4; CAP: Cbl-associated 
protein 
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2.4 Negative regulators and process of insulin signaling termination 
The lipid phosphatases, phosphatase and tensin homolog deleted on 
chromosome ten (PTEN) and Src homology 2 domain containing inositol 5’ 
phosphatase 2 (SHIP2) have been implicated as negative regulators of the 
PI3K pathway [Sasaoka et al., 2006; Clement et al., 2001]. PTEN and SHIP2 
dephosphorylate the PI3K product PIP3 (which is a lipid second messenger), 
thereby blocking the activation of PKB/Akt and the downstream substrates. 
Hence, PTEN is thought to be the main downregulator of this survival pathway 
[Hlobilkova et al., 2003; Mocanu and Yellon, 2007]. 
PTEN is ubiquitously present in normal cells and its degree of activity depends 
on its intracellular concentration. However, its activity can be downregulated 
by phosphorylation or oxidation. The main enzyme responsible for the 
phosphorylation of PTEN is considered to be casein kinase 2 (CK2) [Torres 
and Pulido, 2001], but other kinases have been identified that might also be 
able to phosphorylate PTEN, at least in an in vitro model [Mehenni et al., 
2005]. The opinion is that in its phosphorylated state, PTEN is inactive and as 
such is more stable against proteasomal degradation [Vazquez et al., 2000]. 
PTEN can also be inactivated through oxidation induced by free radicals 
(ROS) [Leslie et al., 2003]. This seems to be the main process regulating 
PTEN activity in the acute setting. Recent documented research suggests that 
insulin, which is known to activate the PI3K/PKB/Akt pathway, may induce the 
activation of nicotinamide adenine dinucleotide phosphate oxidase 
(NADPHOX) which in turn releases ROS [Seo et al., 2005; Espinosa et al., 
2009]. This ROS could be responsible for the inhibition of PTEN [Seo et al., 
2005], which would then be followed by PKB/Akt activation due to PIP3 
accumulation. Furthermore, it has been demonstrated that hydrogen peroxide 
produced at the mitochondrial level can also inhibit PTEN [Conner et al., 
2005].  
Amongst the factors that induce transcription of PTEN are the peroxisome 
proliferator-activated receptor γ-agonists (PPAR-γ) [Teresi et al., 2006] and 
the tumor suppressor p53 [Wang et al., 2005]. The regulation of PTEN and its 
activity is complex and is yet not completely understood, but from what is 
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known, PTEN seems to be an important “switch” in the aim of maintaining 
cellular homeostasis and normal development.  
SHIP is the other lipid phosphatase responsible for insulin signaling 
termination. SHIP-1 has a restricted hematopoietic expression and SHIP-2 is 
ubiquitously expressed [Pesesse et al., 1997; Bruyns et al., 1999] in skeletal 
muscle, heart, placenta and the pancreas and to a lesser extent in the liver 
and kidney [Pesesse et al., 1997; Vollenweider et al., 1999]. The exact 
mechanism of action of SHIP-2, especially in the heart, is still unclear. 
However, over-expression of SHIP-2 in β-cells was shown to inhibit PKB/Akt 
activity and SHIP-null cells exhibit prolonged activation of PKB/Akt upon 
stimulation [Aman et al., 1998]. Research also shows that homozygous mice 
lacking SHIP-2 develop severe neonatal hypoglycaemia or prenatal death and 
adult SHIP-2 heterozygous mutant mice demonstrate insulin sensitivity, which 
is associated with increased translocation of GLUT4 to the plasma membrane 
in response to insulin treatment [Clement et al., 2001].  
In addition, it is worth mentioning that both phosphatases are reported to have 
a negative impact on pathological conditions associated with obesity, such as 
insulin resistance [Wejesekara et al., 2005; Sasaoka et al., 2005] and 
diabetes [Sasaoka et al., 2006; Mocanu and Yellon, 2007]. The activity and/or 
the expression of these phosphatases have been reported to be elevated in 
skeletal muscle and fat tissue under conditions of insulin resistance [Sasaoka 
et al., 2005; Lo et al., 2007]. Therefore blocking PTEN [Oudit et al., 2004] or 
SHIP-2 may prove important, particularly in increasing myocardial survival 
following an ischaemic incident. 
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3. THE LINK BETWEEN OBESITY AND INSULIN RESISTANCE 
Insulin resistance is defined as a reduced responsiveness of a target cell or a 
whole organism to the insulin concentration to which it is exposed [Shanik et 
al., 2008]. The influence of body fat on insulin action is very important and the 
relation between obesity, especially when it is centrally located [Kissebah et 
al., 1989], insulin resistance and the risk for developing type 2 diabetes is well 
recognized.  
There are two general mechanisms that have been identified as links between 
obesity and insulin resistance and they are (i) the role of fatty acids and (ii) the 
role of adipokines and pro-inflammatory cytokines. Figure 1.2 (page 14) is a 
simplified schematic representation of the inter-play between the factors 
thought to be involved in the development of insulin resistance. 
 
3.1 The fatty acid hypothesis 
The major contributor to the development of insulin resistance is an 
overabundance of circulating fatty acids in overweight and obese individuals. 
Elevated levels of free fatty acids reduce glucose uptake by the heart [Boden 
et al., 1994] by increasing muscular and myocardial free fatty acid (FFA) 
uptake and oxidation [Barsotti et al., 2009]. FFA’s are mainly derived through 
the lipolysis of triglyceride-rich lipoproteins from adipose tissue, by the action 
of the cyclic AMP-dependent enzyme lipoprotein lipase [Eckel, 1989, Eckel et 
al., 2005]. During the development of insulin resistance, there is an increased 
amount of lipolysis, which produces more fatty acids. This in turn inhibits the 
antilipolytic effect of insulin, creating additional lipolysis. At cellular level, fatty 
acids and their metabolic products can create insulin resistance by added 
substrate availability and by modifying downstream signaling. Thus in short: 
circulating FFA’s increase hepatic glucose production and diminish inhibition 
of glucose production by insulin, while inhibiting glucose utilization by 
peripheral tissues. A detailed description of fatty acid metabolism follows in 
section 5.3.1 on page 28.  
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3.2 Adipokines and pro-inflammatory cytokines as contributors to 
insulin resistance 
A second, multifaceted mechanism linking obesity to insulin resistance is the 
inflammatory hypothesis. In this section, we will review the effect that (i) 
adipokines, namely leptin and adiponectin and (ii) the pro-inflammatory 
cytokines, secreted by the adipose tissue, have on the development of insulin 
resistance.  
 
3.2.1 Adipokines 
Leptin is an adipokine secreted by the adipocytes and has a vital role in 
energy homeostasis [Pittas et al., 2004]. Although the main target of leptin is 
the appetite centre in the brain, it seems to have effects on insulin action in 
peripheral tissues, as well as on blood vessels and pancreatic β-cells 
[Crowley, 2008; Ronti et al., 2006; Seufert, 2004].  
Insight into the relationship between leptin and insulin resistance, comes from 
studies of leptin deficiency syndromes. Leptin deficient mice (ob/ob) exhibit 
hyperphagia, obesity, hypercortisolemia, infertility and diabetes [Zhang et al., 
1994]. However, once exogenous leptin is administered, these abnormalities 
are reversed [Pelleymounter et al., 1995].  
In obese individuals leptin levels are normally very high and more than 
sufficient to suppress the appetite and increase the metabolism. This, 
however, does not happen and it is believed that obesity may be the result of 
a resistance to leptin [Mark et al., 2002]. It is thought that hyperinsulinaemia 
promotes both insulin resistance and stimulation of leptin production and 
secretion from adipose tissue. This may in turn enhance leptin resistance by 
further desensitizing its signal transduction pathways [Seufert, 2004]. 
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Adiponectin is another anti-inflammatory cytokine that has been shown to both 
improve insulin sensitivity and inhibit many steps in the inflammatory process 
[Nawrocki et al., 2004]. In the liver, adiponectin regulates cells to decrease 
gluconeogenesis [Sheng and Yang, 2008; Combs et al., 2001] and to increase 
fatty acid oxidation. In skeletal muscle, adiponectin increases glucose 
transport and uptake and enhances fatty acid oxidation [Xu et al., 2003]. 
Unlike most adipose tissue products, adiponectin is negatively related to fat 
mass [Kiortsis et al., 2005]. This is observed in studies done on obese human 
patiens and in obese rodent models. Obese patients are found to have lower 
baseline levels of adiponectin compared to healthy individuals [Hotta et al., 
2000; Beltowski, 2003; Matsuzawa et al., 2004]. In obese and type 2 diabetes 
rodent models, insulin resistance is reversed after administration of 
adiponectin [Yamauchi et al., 2004]. Although, obesity is associated with low 
levels of adiponectin, the negative correlation between adiponectin and insulin 
sensitivity is not dependent on adipose tissue alone. Numerous studies report 
that adiponectin levels decrease with increasing BMI, plasma glucose, insulin 
and triglycerides, in rodents and humans [Rajala and Scherer, 2003]    
 
3.2.2 Pro-inflammatory cytokines 
Tumor necrosis factor-α (TNF-α) is one of the primary pro-inflammatory 
cytokines that has been implicated in the pathogenesis of insulin resistance. 
Hotamisligil was one of the first researchers to propose the notion that obesity 
is a low-grade inflammatory state [Hotamisligil et al., 1993]. In this paper, 
Hotamisligil and colleagues (1993) documented that adipose tissue expressed 
TNF-α and that its expression was elevated in the obese state. They 
proposed that the increased expression of TNF-α could contribute to insulin 
resistance. Subsequent studies have largely supported this hypothesis, such 
as studies done by Moller (2000) on TNF-α-null and TNF-α receptor-null mice 
and Fried and Halaas (1998), where they too observed an enhanced TNF-α 
production in adipose tissue obtained from obese and insulin resistant rodents 
and human subjects.  
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In addition, when adipose tissue of obese rodents was compared to their lean 
counterparts, increased levels of multiple pro-inflammatory cytokine gene 
expression were observed [Weisberg et al., 2003; Xu et al., 2003; Kern et al., 
2001] and weight loss reduced the TNF-α levels. Because the above-
mentioned effects appear before the development of insulin resistance and 
during high-fat feeding, it further supports the belief that adipose-derived 
inflammatory factors may have a causal role in the development of high-fat 
diet-induced insulin resistance.  
Various mechanisms have been proposed to explain the effect of TNF-α on 
the development of obesity-related insulin resistance. Possible mechanisms 
include increased release of FFA by adipocytes through additional lipolysis of 
adipose tissue triglyceride stores [Eckel et al., 2005], reduction in adiponectin 
synthesis [Bruun et al., 2003] and impairment of insulin signaling [Greenberg 
and McDaniel, 2002; Hotamisligil and Spiegelman, 1994].   
 
Interleukin-6 (IL-6) is a circulating cytokine, which is normally secreted by 
activated macrophages and lymphocytes. However, in non-acute 
inflammatory conditions its major source is adipose tissue [Mohamed-Ali et 
al., 1997]. IL-6 is a pleiotropic cytokine (cytokine affecting the activity of 
multiple cell types) and its effects range from inflammation to tissue injury 
[Papanicolaou et al., 1998]. For this review, we will only be focusing on its link 
to insulin resistance.  
The link between IL-6 and insulin resistance is supported by epidemiological 
studies as well as genetic studies [Klover et al., 2003; Hebert et al., 2006; Qi 
et al., 2006]. There is a positive correlation between plasma IL-6 levels and 
human obesity and insulin resistance [Vozarova et al., 2001, Kern et al., 2001; 
Pradhan et al., 2001; Papanicolaou et al., 1998]. As with TNF-α, IL-6 is 
thought to exert its adverse effects by increasing circulating FFA with its well 
described adverse effects on insulin sensitivity [Boden and Shulman, 2002], 
enhancing hepatic glucose production and decreasing adiponectin secretion 
[Fasshauer et al., 2003]. Weight loss is found to significantly reduce IL-6 
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levels in both adipose tissue and serum [Bastard et al., 2000]. In the clinical 
set-up, elevated levels of IL-6 are used as a predictor of type 2 diabetes 
development [Pradhan et al., 2001] and risk of future myocardial infarction 
[Ridker et al., 2000]. 
 
In addition to the FFA hypothesis and the involvement of adipokines and pro-
inflammatory cytokines, growing evidence links plasminogen activator 
inhibitor-1 (PAI-1) with obesity and insulin resistance. Adipose tissue has 
been found to be a key source of PAI-1, with the bulk production in visceral 
adipose tissue [He et al., 2003]. PAI-1 is a key regulatory protein in processes 
such as tissue fibrinolysis, cell migration, angiogenesis and tissue remodeling 
[Lijnen, 2005]. It has been found that PAI-1 deficient mice have reduced 
adiposity and an improved metabolic profile [Schafer et al., 2001] and PAI-1 
deficiency attenuated diet-induced obesity and insulin resistance in C57BL/6 
mice [De Taeye et al., 2006]. Furthermore, in mouse models, the absence or 
inhibition of PAI-1 through genetic alteration in adipocytes protects against 
insulin resistance by promoting glucose uptake and adipocyte differentiation 
via increased PPAR-α expression [Liang et al., 2006]. 
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Figure 1.2: Simplified, schematic representation of the inter-play between 
factors involved in the development of insulin resistance. FFA’s are released in 
abundance from an expanded adipose tissue mass. In the liver, FFA’s lead to an 
increased production of glucose, triglycerides and secretion of VLDL. Associated 
abnormalities include reductions in HDL cholesterol and an increased density of LDL. 
FFA’s also reduce insulin sensitivity in muscle by inhibiting insulin-mediated glucose 
uptake. Associated defects include a reduction in glucose conversion to glycogen and 
increased lipid accumulation in triglyceride. Increases in circulating glucose and FFA 
increase pancreatic insulin secretion resulting in hyperinsulinemia. Contributory to the 
insulin resistance produced by excessive FFA is the paracrine and endocrine effect of 
the proinflammatory state. The enhanced secretion of IL-6 and TNF-α among others 
results in more insulin resistance and lipolysis of adipose tissue triglyceride stores to 
circulating FFA. The increased IL-6 may enhance hepatic glucose production, the 
production of VLDL by the liver and insulin resistance in muscle. Cytokines and FFA’s 
also increase the production of PAI-1 by the liver that complements the 
overproduction of PAI-1 by adipose tissue. This results in a pro-thrombotic state. 
Adapted from Eckel et al., (2005). VLDL: very low-density lipoproteins; HDL: high-
density lipoproteins; LDL: low-density lipoproteins; FFA: free fatty acids; PAI-1: 
plasminogen activator inhibitor-1; TNFα:  tumour necrosis factor-α 
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4. THE LINK BETWEEN INSULIN RESISTANCE AND DIABETES 
Insulin resistance is the earliest detectable clinical manifestation in the 
development of diabetes. The section below describes this link. 
  
4.1 Diabetes mellitus 
Wild et al. (2004) estimated, based on data obtained from the World Health 
Organization, that there were approximately 171 million individuals with 
diabetes mellitus at the start of 2000 and that this number would increase to 
366 million by 2030.  
Diabetes mellitus is a disorder in the metabolism of blood glucose. It occurs 
when the body’s production of insulin is inadequate or when the body no 
longer responds effectively to endogenous insulin. Both these abnormal 
responses lead to chronic hyperglycaemia, accompanied by abnormal 
metabolism of carbohydrate, fat and protein. Diabetes can be a life threatening 
condition if not detected early and continually monitored. According to WHO 
calculations, almost 3 million deaths annually are as a result of diabetes [Wild 
et al., 2004].  Diabetes mellitus is classified into four major groups: 1) type 1 
diabetes, caused by the destruction of pancreatic β-cells and thus 
characterized by the inability of the β-cell’s to synthesize insulin [Daneman, 
2006]; 2) type 2 diabetes, characterized by insulin resistance and β-cell 
dysfunction, whereby the body becomes resistant to the effects of insulin, 
presumably due to defects in the insulin signaling pathway [Olefsky et al., 
1982; DeFronzo et al., 1979; Turner et al., 1979]; 3) other types of diabetes, 
including genetic diabetic forms [Winter, 2003; Simonen et al., 2006], 
pancreas disorders and endocrinopathies [Resmini et al., 2009]; and 4) 
gestational diabetes, with diabetes onset during pregnancy [Serlin and Lash, 
2009; Alwan et al., 2009].  
For the purpose of this review, only type 1 and type 2 diabetes will be 
discussed in further detail.  
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4.1.1 Type 1 diabetes mellitus 
Type 1 diabetes accounts for about 5 to 10% of all cases of diabetes 
[Daneman, 2006]. Because the manifestation of type 1 diabetes was thought 
to only develop in childhood or adolescence this form of diabetes was formerly 
termed juvenile-onset diabetes or insulin-dependent diabetes mellitus. 
However, it is now recognized that type 1 diabetes can occur at any age 
[Seissler, 2008].  
It is widely accepted that type 1 diabetes results from a chronic autoimmune 
response directed against the insulin-producing β-cells in the islets of 
Langerhans. The destruction may occur over months or even years and can 
eventually result in complete loss of endogenous insulin supply. The 
autoimmune trigger against the β-cells is most likely caused by environmental 
agent(s) in conjunction with a predisposing genetic background. The 
mechanisms of β-cell damage in type 1 diabetes is not yet completely 
understood, but it is thought to involve mechanisms such as Fas/FasL, 
perforin/granzyme, reactive oxygen and nitrogen species and pro-
inflammatory cytokines [Yoon and Jun, 2005; Cnop et al., 2005; Eizirik and 
Mandrup - Poulsen, 2001]. Binding of these cytokines to their receptors on the 
β-cells activates MAP-kinases and the transcription factors STAT-1 and 
NFkappa-β. This is known to bring about functional impairment, endoplasmic 
reticulum stress and ultimately apoptosis [Eizirik and Mandrup - Poulsen, 
2001; Eizirik et al., 2008].  
This response of β-cell destruction ultimately leads to insulin deficiency that 
requires hormone replacement therapy to restore physiological control of 
blood glucose [Daneman, 2006]. Patients thus require lifelong insulin for 
survival as there is no cure for this immune-mediated disease.  
Whole pancreas transplantation [Bertuzzi et al., 2006], pancreatic islet 
transplantation [Hakim, 2006] and gene therapy approaches have all been 
used in the aim to prevent the morbidity and mortality associated with this 
complex disease [Bagley et al., 2008]. Recently, stem cell transplantation 
[Ramiya et al., 2000; Seaberg et al., 2004; Suzuki et al., 2004], β-cell 
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replication [Bouwens and Rooman, 2005], reprogramming of mature β-cells 
[Bonner-Weir et al., 2000 (b), 2004; Gao et al., 2003] and in vivo regeneration 
of β-cells [Dor et al., 2004], have also been tested as possible therapies, with 
promising results.  
There are reported cases of individuals that have, at the time of diagnosis, a 
residual β-cell function sufficient to prevent the development of acute 
metabolic ketosis [Seissler, 2008]. This late stage of clinical presentation and 
the absence of immediate insulin requirement often lead to a misclassification 
as type 2 diabetes. Autoimmune destruction of the β-cells of the pancreas is 
more than 90% complete by the time hyperglycaemia becomes clinically 
evident in individuals with type 1 diabetes mellitus [Ryu et al., 2001]. Thus, 
drug treatment aimed at preventing or prolonging the onset of this disease, by 
prolonging the “window period”, would therefore be beneficial in a clinical 
setup. 
 
4.1.2 Type 2 diabetes mellitus  
Type 2 diabetes has a strong polygenic background on which environmental 
factors act and largely determines the clinical presentation. This disease 
usually develops in adulthood and is linked to obesity, lack of physical activity 
and unhealthy diets. Type 2 diabetes is the more common type of diabetes 
and affects 90 – 95% of patients with diabetes [Moller, 2001]. Although a 
positive correlation between BMI and risk for type 2 diabetes mellitus was 
identified in studies such as these two large epidemiologic reports - the 
Nurses’ Health Study [Colitz et al., 1995; Hu et al., 2001] and the Health 
Professionals’ Follow-up Study [Chan et al., 1994], not everyone who is obese 
has type 2 diabetes mellitus and not everyone who has type 2 diabetes 
mellitus has an elevated BMI [Colitz et al., 1995; Chan et al., 1994].   
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4.1.2.1 Pancreatic cell function  
In recent years major advances have been made in our understanding of how 
the pancreas develops [Servitja and Ferrer, 2004; Habener et al., 2005; 
Collombat et al., 2006]. A normal pancreas contains approximately 1,000,000 
islets of Langerhans, in which different types of endocrine cells reside 
[Marchetti et al., 2008]. Four main cell types exist in the islets, namely, the 
insulin secreting β-cells, which represent the majority of islet endocrine cells 
(60 to 80%), followed by glucagon containing α-cells (20 to 30%), 
somatostatin containing δ-cells (5 to 15%) and pancreatic polypeptide cells 
[Marchetti et al., 2008]. The α- and β-cells monitor the concentration of 
glucose in the blood and secrete hormones with opposite effects. Both these 
cell types play a pivotal role in glucose homeostasis of a healthy human 
subject, by ensuring that the individuals’ plasma glucose concentration 
remains within the narrow physiological range of 4 to 8 mmol/L (fasting blood 
glucose level) [Andrews et al., 1998]. The amount of insulin released by the β-
cells varies according to the nature, administration of the stimulus and the 
existing glucose concentration [Guillausseau et al., 2008]. The released 
insulin stimulates the uptake of glucose by cells and its conversion to 
glycogen in the liver and muscle. In contrast, the islet α-cells secrete 
glucagon, which is the hormone responsible for stimulating the breakdown of 
glycogen to glucose in the liver, increasing the blood glucose levels. The β-
cells are the cells of interest for this review.  
 
4.1.2.2 β-cell mass 
Over the past few decades, it has become clear that the β-cell mass is 
dynamic, with a significant capacity to adapt to changes in insulin demand. 
For example, non-diabetic obese individuals have more β-cells than lean 
individuals or obese individuals with type 2 diabetes [Nielsen et al., 1992]. 
Optimal control of blood glucose concentrations depends on delicate changes 
in insulin production and secretion by the pancreatic β-cells. For this reason, it 
is very important for β-cell mass to be closely regulated.  
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β-cell mass is determined by the interplay between β-cell mass expansion and 
reduction mechanisms. Expansion can occur through increases in β-cell 
hypertrophy, hyperplasia and neogenesis. In contrast, reduction occurs 
through β-cell atrophy or death by means of apoptosis [Bonner-Weir and 
Weir, 2005; Dor et al., 2004; Halban, 2004; Marchetti et al., 2008; Rhodes, 
2005]. Accordingly, β-cell mass is achieved through the manipulation of any of 
these mechanisms, alone or in combination.  
Under normal conditions, the main process involved in β-cell mass directly 
after birth, is replication, which is followed by the process of neogenesis 
[Bonner-Weir, 2001; Marchetti et al., 2008; Rhodes, 2005]. During this phase 
of development, the rate of apoptosis is low, which allows for cell growth. 
Throughout childhood and adolescence there is a balance between 
replication, neogenesis and apoptosis. This results in adequate β-cell mass 
throughout adulthood. During old age, however, apoptosis increases to a point 
whereby it outweighs neogenesis and replication, which leads to a β-cell mass 
decrease [Marchetti et al., 2008; Rhodes, 2005].  
During pathological conditions such as insulin resistance, due to obesity, the 
pancreatic β-cell mass is increased [Prentki and Nolan, 2006]. This increased 
β-cell mass leads to enhanced insulin secretion (hyperinsulinaemia), to 
compensate for the increased insulin demand [Weyer et al., 1999; Kahn et al., 
1993; Prentki and Nolan, 2006]. However, if hyperinsulinaemia continues the 
β-cells are unable to fully compensate for the decreased insulin sensitivity and 
start to deteriorate in function [Kahn, 2001; Perley and Kipnis, 1966; Polonsky 
et al., 1988]. This leads to β-cell dysfunction and progressive loss [Kahn, 
2003; Ferrannini and Mari, 2004; Buchanan, 2003] due to apoptosis and the 
subsequent development of type 2 diabetes [Buchanan, 2001; Butler et al., 
2003].  
The apoptosis seen in patients with type 2 diabetes is thought to be because 
of glucotoxicity or lipotoxicity. Chronic exposure of rodent β-cells to high 
glucose levels displays alterations in β-cell phenotype, alterations that could 
have resulted from cytokine-, oxidative stress- or endoplasmic reticulum (ER) 
stress- induced changes in gene expression and cell survival [Cnop et al., 
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2005]. A rise in cytoplasmic free fatty acid levels leads to increased ceramide 
formation, which induces iNOS, resulting in NO mediated β-cell apoptosis 
[Cnop et al., 2005; Shimabukuro et al., 1997; Prentki and Nolan, 2006].  
β-cell neogenesis (or regeneration) represents a major goal of therapy for 
diabetes. Successfully unraveling the origin of β-cells during pancreatic 
neogenesis could lead to restoration of β-cell mass in individuals with type 1 
diabetes and enhanced β-cell compensation in type 2 patients. Therefore, it 
would be clinically relevant to investigate the transcription factors that are 
involved in the process of β-cell neogenesis and potential methods of 
manipulating these transcription factors. 
 
4.1.2.3 β-cell neogenesis and transcription factors involved 
Neogenesis is an important component of β-cell mass expansion during 
development. The mechanism of islet neogenesis remains poorly understood, 
despite its potential applications in regenerative or replacement therapies for 
the treatment of type 1 and type 2 diabetes.  
β-cell neogenesis can occur through two pathways: (i) stem/progenitor cell 
activation and/or (ii) transdifferentiation of adult pancreatic cells [Xu et al., 
2008]. β-cell mass expansion derived from stem/progenitors cells, refers to 
the differentiation of a dormant cell expressing primordial markers of insulin 
producing β-cells. There is, however, still controversy around the existence 
and classification of such pancreatic stem cells [Abraham et al., 2002; Dor et 
al., 2004; Seaberg et al., 2004]. Very little is known about these stem cells 
that reside within the islet itself [Zulewski et al., 2001; Petropavlovskaia and 
Rosenberg, 2002] or in the pancreatic ducts [Bonner-Weir et al., 2000 (a); 
Zhao et al., 2007]. In contrast, transdifferentiation of adult cells refers to the 
ability of one mature cell phenotype to differentiate to another cell phenotype. 
The hypothesis here is that the new β-cells are derived directly from the 
transdifferentiation of mature, differentiated duct or acinar pancreatic cells or 
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through a process of dedifferentiation to a more primitive intermediate cell, 
followed by redifferentiation into an insulin-producing cell. 
It is believed that all specialized endocrine as well as exocrine cells of the 
pancreas are derived from the same precursor cells which reside within the 
endoderm [Bouwens and Rooman, 2005; Percival and Slack, 1999; Wilson et 
al., 2003]. Differentiation of endocrine progenitor cells into hormone-producing 
islet cells is tightly regulated by the chronological expression of numerous 
transcription factors. With in situ hybridization screening Zhou and colleagues 
(2007) identified more than 1100 transcription factors with cell-type-specific 
expressions in the embryonic pancreas. Of those, at least 20 transcription 
factors were found to be expressed in mature β-cells and their immediate 
precursors and 9 genes exhibited β-cell developmental phenotypes when 
mutated [Murtaugh and Melton, 2003; Jensen, 2004]. A combination of the 
transcription factors pancreatic and duodenal homeobox 1 (Pdx1), neurogenin 
3 (Ngn3) and musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) 
was found to be required in the differentiation of endocrine progenitors to 
hormone-producing β-cells [Zhou et al., 2008].  
The homeodomain transcription factor Pdx1 is one of the earliest genes 
expressed in the developing pancreas, which is essential for pancreas 
development and all pancreatic cells are thought to arise from a common 
Pdx1 expressing progenitor cell [Gu et al., 2002]. In the differentiated β-cell, 
Pdx1 is a glucose responsive regulator of insulin gene expression [Petersen 
et al., 1998]. When transduced Pdx1 in cultured pancreatic ducts interacted 
with the insulin gene promoter, the interaction triggered insulin gene 
expression [Noguchi et al., 2003; Wilson et al., 2003]. This suggests that 
ductal Pdx1 expression has effects on neighbouring cells within the pancreatic 
duct and then may induce the first steps of β-cell differentiation. Research 
done by Holland and colleagues (2005) demonstrated that when Pdx1 in adult 
mice was repressed, the expression of insulin and glucagon was impaired and 
this led to diabetes within 14 days. These findings confirm that Pdx1 is 
required for β-cell function in the adult pancreas [Holland et al., 2005] and that 
Pdx-1 may have the capacity to reprogram extra-pancreatic tissue towards a 
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β-cell phenotype, which may provide a valuable approach for generating β-
cells, suitable for replacing impaired β-cell function found in diabetes. 
During pancreas development, all endocrine cell types are derived from 
progenitors that express the transcription factor Ngn3 [Gradwohl et al., 2000]. 
Embryos lacking the Ngn3 transcription factor lack all endocrine cell types and 
die two to three days after birth due to diabetes [Gradwohl et al., 2000]. 
According to research done by Xu and colleagues (2008), there is a 10-fold 
increase in dividing β-cell number, following partial duct ligation and that the 
appearance of these new β-cells correlates with activation of Ngn3. This 
suggests that Ngn3 plays a key role in β-cell regeneration.  
MafA is a recently isolated β-cell-specific transcription factor that functions (in 
the presence of Pdx1) as a potent activator of insulin gene transcription in the 
developing β-cell [Kaneto et al., 2007; Matsuoka et al., 2004]. Under diabetic 
conditions, expression and activity of Pdx1 and MafA in β-cells are reduced, 
which inevitably leads to suppression of insulin biosynthesis and secretion. 
Together Pdx1 and MafA play an important role inducing β-cells and could be 
a therapeutic target for diabetes [Kaneto et al., 2007]. 
 
4.1.2.4 Current therapies for type 2 diabetes 
The mechanisms involved in the development of this disease are an active 
field of research that may bring about the development of newer and safer 
therapies. The current available therapies do not successfully enable patients 
with type 2 diabetes to reach glycaemic goals. Even with intensive treatment, 
patients with type 2 diabetes may face spikes in blood glucose levels after 
meals, weight gain and a loss of effectiveness of their treatments over time 
[Pearson, 2009; Moller, 2001]. The present therapies mainly rely on the 
approaches to reduce hyperglycaemia by means of oral hypoglycaemic 
agents.  
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Table 1: Current therapies used for managing hyperglycaemia in type 2 
diabetes 
Drug  Description of effects Documented side-effects 
Metformin Suppresses gluconeogenesis and 
thus reduce hepatic glucose 
production [Correia et al., 2008; 
Pearson, 2009]  
Gastrointestinal side-effects, 
such as diaree and impaired 
digestion [Bosi, 2009] 
Sulphonylureas Stimulates insulin secretion by β-
cells in a non-glucose dependent 
manner [Kar and Holt, 2008; 
Pearson, 2009]  
Weight gain, hypoglycaemia, 
gastrointestinal distress, 
dermatological reactions, 
haematological changes, 
ocular problems 
inappropriate secretion of 
antidiuretic hormone [Salas 
and Caro, 2002] 
Thiazolidinediones 
(TZD) 
PPARγ agonist, which enhance 
insulin action primarily through 
indirect effects on lipid 
metabolism [Pearson, 2009; 
Edgerton et al., 2009] 
Osteoporosis [Meier et al., 
2009] 
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5. OBESITY AND CARDIOVASCULAR DISEASE  
Numerous studies have linked obesity to an increased risk of developing 
cardiovascular disease. This is due to the multitude of risk factors associated 
with obesity, such as hypertension, diabetes and dyslipidaemia [Reaven 1988, 
Seidell et al., 1996; Lopaschuk et al., 2007]. Presently, cardiovascular 
diseases represent the most important health risk factors because they are 
responsible for more than 50% of total mortality [Ostadal, 2009]. According to 
projections made in 2009 by the WHO, cardiovascular diseases claim 17.1 
million lives annually. The types of cardiovascular diseases include, ischaemic 
heart disease, cerebrovascular disease (or commonly known as a stroke), 
congestive heart failure, coronary artery disease and peripheral vascular 
disease. 
Among these cardiovascular diseases, ischaemic heart disease (IHD) is the 
leading cause of death in the industrial world and according to the WHO will 
be the major global cause of morbidity and mortality by the year 2020 [Murray 
and Lopez, 1997].  
 
5.1 Ischaemic heart disease  
Ischaemic heart disease, or otherwise called myocardial ischaemia, develops 
as a consequence of a number of risk factors and always coexists with other 
disease states, which include systemic arterial hypertension and related left 
ventricular hypertrophy, hyperlipidemia, athrosclerosis, diabetes, insulin 
resistance, heart failure as well as ageing [Ferdinandy et al., 2007]. IHD 
develops when there is an imbalance between the normal rate of oxygen 
delivery to the myocardium required for cardiac muscle contraction and the 
actual rate of oxygen delivery to the myocardium [Stanley, 2001]. Diabetic 
patients, both type 1 and type 2, have a 2-fold increased risk of sustaining 
myocardial ischaemia, as well as 2.4-fold increased mortality post-ischaemia 
[Haffner, 1999; Taegtmeyer et al., 2002]. An increased susceptibility of the 
myocardium to ischaemia in the diabetic and dysmetabolic state leads to an 
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increased infarct size and this has been suggested to play a key role in the 
poor prognosis of myocardial infarction in type 2 diabetes mellitus patients 
[Song and Hardisty, 2008; Haffner, 1999].  
Infarct size is an important determinant of mortality and heart failure after 
myocardial infarction [Burns et al., 2002]. Pharmacological agents, such as 
insulin [Ryu et al., 1999], urocortin [Brar et al., 2002], atorvastatin [Bell and 
Yellon, 2003 (a)], bradykinin [Bell and Yellon, 2003 (b)], erythropoietin [Bullard 
et al., 2005] and glucagon-like peptide 1 (GLP-1) [Bose et al., 2005], which are 
known to activate PI3K/PKB/Akt signaling pathways, have all been shown to 
reduce necrotic tissue and thus protect against myocardial infarction. 
In acute myocardial infarction, the primary event is most commonly a 
thrombus in an atherosclerotic coronary artery, which is due to a process 
termed atherosclerosis. Cytokines and FFA increase the production of 
fibrinogen and plasminogen activator inhibitor-1 (PAI-1) by the liver, which 
results in a pro-thrombotic state (refer to Figure 1.2). Fibrinogen is a clotting 
factor and the increased concentration thereof causes hypercoagulability, 
which is a potentially dangerous condition in which blood coagulates 
excessively. Studies have shown that hypertension, which has a strong 
association with obesity, has both a role in the genesis of atherosclerosis and 
in the extent and instability of the atherosclerotic plaque [Davies, 1991; 
Megnien et al., 1996; Sipahi et al., 2006].  
Atherosclerosis is a progressive disease characterized by the accumulation of 
calcium crystals, smooth muscle cells, macrophages, fatty streaks and 
inflammatory mediators [Ross, 1999] in arteries, to form plaques. Plaques can 
increase in size to such an extent that they significantly reduce the vascular 
lumen (inside space of the artery) diameter, thus reducing the blood flow 
through an artery. However, the bulk of the damage occurs when these 
plaques become fragile and ruptures, leading to the expulsion of pro-
thrombotic factors into the bloodstream. Ruptured plaques cause thrombi 
formation that can block blood flow or break off and travel to another part of 
the body, where it lodges into smaller arteries, capillaries or veins. If the 
thrombus occludes a blood vessel that feeds the heart, the myocardium below 
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the occlusion is left without sufficient oxygen supply to meet metabolic 
demand, leading to compromised myocardial viability and cardiac function 
[Ross, 1999; Opie, 1991]. 
Apart from large vessel disease and atherosclerosis, which are very common 
in diabetes, diabetic cardiomyopathy (DCM) is a distinct primary disease 
process, independent of coronary artery disease, which leads to heart failure 
in diabetic patients [Avogaro et al., 2004].  
 
5.2 Diabetic cardiomyopathy 
Diabetes mellitus results in a marked increase in cardiac disease and this is 
partly due to diabetic cardiomyopathy. Diabetic cardiomyopathy can be 
defined as abnormal myocardial performance or structure in the absence of 
coronary heart disease and hypertension [Severson et al., 2003; Shehadeh 
and Regan, 1995]. Rubler and colleagues (1972), who reported autopsy data 
from four patients with diabetic renal microangiopathy and dilated left 
ventricles in the absence of other common causes, made the first report of 
diabetic cardiomyopathy more than 30 years ago. The concept of diabetic 
cardiomyopathy remains slightly vague, despite nearly 40 years of basic and 
clinical research [Boudina and Abel, 2007]. This could be due to the lack of 
consensus over its definition and the myocardial abnormalities that are often 
overlooked.  
The pathogenesis of this disease is indeed complex, however, alterations in 
cardiac energy metabolism have been proposed as contributing mechanisms 
[Jagasia and McNulty, 2003]. Hyperglycaemia is also considered to play a 
central part in the pathophysiology of this disease, because it can trigger 
several responses, both adaptive and maladaptive. Several epidemiologic 
studies [Palmieri et al., 2001; Bella et al., 2001; Liu et al., 2001; Rutter et al., 
2003] suggest that there is an association between diabetic cardiomyopathy 
and the presence of cardiac hypertrophy and myocardial stiffness, both being 
independent of hypertension.  
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Finding treatments for diabetic patients with underlying heart diseases, 
presents as a challenge, due to the complexity of the pathophysiology and the 
poor prognosis of these comorbidities. Therefore, investigation of the cellular 
metabolism and mechanisms of interaction of these diseases is of particular 
interest. 
 
5.3 Cardiac energy metabolism 
The heart consumes more energy than any other organ, cycling approximately 
6 kg of adenosine triphosphate (ATP) every day while circulating nearly 10 
tons of blood throughout the body [Neubauer, 2007]. Under normal coronary 
blood flow, almost all (> 95%) ATP formation in the heart is generated during 
oxidative phosphorylation in the mitochondria and the remaining 5% is 
generated during glycolysis and guanosine triphosphate (GTP) formation in 
the citric acid cycle. The myocardium has a relatively low ATP content (± 5 
µmol.g wet wt) and a high rate of ATP hydrolysis (± 0.5 µmol.g wet wt-1.s-1 ) at 
rest, which means that there is a complete turnover of the mitochondrial ATP 
pool approximately every 10 sec under normal conditions [Ingwall, 2002; 
Opie, 1991].  
The cardiac muscle has a high demand for energy to maintain cellular 
homeostasis and normal contractile function. It is well known that under 
normal conditions the heart utilizes a host of different substrates, amongst 
which fatty acids are the major fuel for the generation of energy, with glucose 
following in second place. The heart switches between these substrates to 
accommodate different conditions, during both normal and pathological 
situations [Rodriques et al., 1995; Stanley et al., 1997 (b)]. Under 
circumstances of stress such as pathological hypertrophy or myocardial 
ischaemia, the substrate preference shifts from free fatty acids to glucose. 
This shift is capable of generating high-energy phosphates through both 
glycolytic flux as well as oxidation of the glycolytic intermediate, pyruvate 
[Bertrand et al., 2008].  
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Diabetes has a marked influence on cardiac metabolism, due to the altered 
substrate supply, impaired insulin action and metabolic changes observed in 
the diabetic heart [Taegtmeyer et al., 2002; Young et al., 2002].   
 
5.3.1 Fatty acid metabolism  
In the healthy human heart fatty acids are the main suppliers of energy, at 
approximately 60 to 90% [Opie, 1998; Stanley et al., 1997 (b); Balaban et al., 
1986]. The rate of fatty acid uptake by the heart is primarily determined by its 
plasma concentration [Lopaschuk et al., 1994 (a); Wisneski et al., 1987], 
which is in turn regulated by their net release from triglycerides in adipocytes. 
Free fatty acid concentration can vary in the range of 0.2 to 0.8 mM during the 
course of the day in healthy individuals. Under conditions of metabolic stress, 
such as ischaemia, diabetes, or starvation, concentrations can increase to 
levels up to about 1.0 mM [Lopaschuk et al., 1994 (b)].   
Insulin suppresses fatty acid levels, which is the reason why fatty acid levels 
are low after a meal. In contrast, during fasting, when insulin is low and 
catecholamines are high, the plasma fatty acid concentration is elevated, 
resulting in a high rate of fatty acid uptake and oxidation by the heart. 
Alternatively, noradrenaline increases fatty acid release from adipocytes 
during physical exercise, fasting or myocardial ischaemia. Diabetic patients 
(both types 1 and 2) have elevated levels of fatty acid, due to low insulin 
levels and/or resistance to the normal insulin-induced suppression of fatty acid 
release from adipocytes. This increase in fatty acid oxidation has an important 
suppressive effect on carbohydrate oxidation in the heart through inhibition of 
glycolysis in the cytosol and pyruvate dehydrogenase in the mitochondria, 
which in turn leads to impaired myocardial energy production and the 
accumulation of glycolytic intermediates and ceramide, which enhances 
apoptosis [Eckel and Reinauer, 1990; Liedtke et al., 1988]. The toxic 
intermediates resulting from free fatty acid metabolism [Rodrigues et al., 1998; 
Yazaki et al., 1999] (so-called lipotoxicity) can impair myocyte calcium 
handling, worsening myocardial mechanics. 
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Fatty acids enter the cardiomyocyte by one of two processes: either by 
passive diffusion or by protein-mediated transport across the sarcolemma 
[Van der Vusse et al., 2000], where it is converted to acyl-CoA. Fatty acids are 
oxidized via the process of β-oxidation in the mitochondria, where energy is 
released in the form of nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) for the electron transport chain and the 
subsequent formation of ATP by oxidative phosphorylation [Lopaschuk et al., 
1994 (a)].  
The mitochondrial inner membrane is not permeable to long-chain acyl-CoA 
and the acyl-CoA must thus first be transferred from the cytosol into the 
matrix, by a carnitine-dependent transport system [Kerner and Hoppel, 2000]. 
The fatty acids must be converted to fatty acylcarnitine by the enzyme 
carnitine palmitoyl transferase 1 (CPT-1), in order to cross the inner 
mitochondrial membrane [Lopascuk et al., 1994 (a)]. This process occurs 
between the inner and outer membrane of the mitochondria (refer to Figure 
1.3A). Thereafter, carnitine acyltranslocase transfers this long-chain 
acylcarnitine across the inner mitochondrial membrane in exchange for free 
carnitine. Lastly, carnitine palmitoyltransferase II (CPT-II) regenerates long-
chain acyl CoA in the mitochondrial matrix, where β-oxidation occurs.   
β-oxidation involves four reactions and it is a process that repeatedly cleaves 
off two carbon acetyl-CoA units [Opie, 1998]. The first step is catalyzed by 
acyl-CoA dehydrogenase, followed by 2-enoyl-CoA hydratase and then 3-
hydroxyacyl-CoA dehydrogenase. The final step is 3-ketoacyl-CoA thiolase, 
which regenerates acyl-CoA for another round of β-oxidation and releases 
CO2 and acetyl-CoA for the citric acid cycle. Acyl-CoA dehydrogenase and 3-
hydroxyacyl-CoA dehydrogenase generate FADH2 and NADH respectively 
and the acetyl-CoA formed from β-oxidation generates more NADH and 
FADH2 in the citric acid cycle [Stanley et al., 2005].  
As mentioned above, the long-chain fatty acyl-CoA, can be converted to long-
chain fatty acylcarnitine by carnitine palmitoyltransferase I (CPT-I) [Lopaschuk 
et al., 1994 (a)], but it can also be esterified to triglyceride by 
glycerolphosphate acyltransferase [Coleman et al., 2000; Lopaschuk et al., 
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1994 (a)]. Under normal cardiac conditions, between 70 to 90% of the fatty 
acids that enter the cell are converted to acylcarnitine and immediately 
oxidized and the remaining 10 to 30% enter the triglyceride pool in the heart 
[Lopaschuk et al., 1994 (a); Saddik and Lopaschuk, 1991].  
These high plasma fatty acid levels could contribute to the impaired cardiac 
function observed in diabetes. Exposing the heart to high levels of fatty acids 
can cause accumulation of lipids (cardiac lipotoxicity) [Lee et al., 2004; Wang 
and Unger, 2005]. This excessive accumulation of lipids within nonadipose 
tissue could lead to the increase in the intracellular pool of long-chain fatty 
acyl-CoA, thereby providing fatty acid substrate for nonoxidative processes, 
which can lead to cell dysfunction, insulin resistance and potentially apoptotic 
cell death [Lee et al., 2004; Taegtmeyer et al., 2002; Young et al., 2002]. 
 
5.3.2 Glucose and lactate metabolism 
Glucose and lactate supply approximately 10 to 40% of the cardiac energy 
requirements [Opie, 1998; Stanley et al., 1997 (a); Gertz et al., 1988; 
Wisneski et al., 1985; Wisneski et al., 1990]. The transport of glucose into the 
cardiomyocyte is via glucose transporters (mainly insulin-dependent-GLUT4 
and to a lesser extent insulin-independent-GLUT1) and this is regulated by the 
transmembrane glucose gradient and the content of glucose transporters in 
the sarcolemma. Myocardial glucose use is substantially reduced in diabetes, 
due to diminished glucose uptake [Rodrigues et al., 1998].  
Glucose is utilized by the myocardium and processed in one of two ways: it is 
either stored as glycogen, or broken down through the process of glycolysis. 
The glycolytic pathway converts glucose-6-phosphate and NAD+ to pyruvate 
and NADH, generating two ATP molecules for each glucose molecule (refer to 
Figure 1.3A). The first irreversible step of the glycolytic pathway is catalized 
by phosphofructokinase-1 (PFK-1), which is a key regulatory enzyme. PFK-1 
makes use of ATP to generate fructose-1,6-bisphosphate and it is stimulated 
by adenosine diphosphate (ADP) and adenosine monophosphate (AMP). 
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PFK-1 can be inhibited by a fall in pH and the extent of the inhibition of PFK-1 
depends on the ATP levels, with the inhibition being greatest when ATP levels 
are high. Citrate is a negative allosteric regulator of PFK-1 and links changes 
in mitochondrial oxidative metabolism to glycolysis. Philip Randle proposed 
that this accumulation of citrate is responsible for the decrease in glycolysis 
that occurs in various tissues when fatty acid oxidation increases [Garlind et 
al., 1963; Newsholme and Randle, 1964; Randle et al., 1968; Randle et al., 
1970].  
The pyruvate formed during glycolysis can either be converted to lactate, 
decarboxylated to acetyl-CoA, or carboxylated to oxaloacetate or malate. 
Pyruvate decarboxylation is catalyzed by pyruvate dehydrogenase (PDH) 
[Randle, 1968]. PDH is inactivated by PDH kinase (PDK) and activated by 
PDH phosphatase [Randle, 1968; Randle and Priesman, 1996]. PDK has four 
isoforms, PDK-4 being the predominant form in the heart. The expression of 
PDK-4 is induced by starvation, diabetes and peroxisome proliferater 
activated receptor-α (PPARα) ligands [Harris et al., 2001; Wu et al., 2001] 
(refer to Figure 1.3B). During fasting as well as diabetes, there is high 
circulating lipid and intracellular accumulation of long-chain fatty acids and this 
enhances the PPARα-mediated PDK-4 expression, which leads to a greater 
phosphorylation inhibition of PDH and thus less oxidation of pyruvate derived 
from glycolysis and the oxidation of lactate [Horwich et al., 2001; Wu et al., 
2001]. Glucose and pyruvate oxidation as well as the activity of PDH in the 
heart are reduced by elevated rates of fatty acid oxidation, such as occurs if 
plasma levels of free fatty acids are elevated. A well recognized fact is that the 
oxidation of glucose and lactate is strongly inhibited by high rates of fatty acid 
oxidation in the heart [Opie, 1998; Stanley et al., 1997 (b); Wisneski et al. 
1985; Wisneski et al. 1990; Randle et al., 1963; Randle et al., 1964].  
An additional source of glucose-6-phosphate for the heart comes from 
intracellular glycogen stores. The glycogen pool in the heart is much smaller 
(± 30 µmol.g wet wt) compared to skeletal muscle (± 150 µmol.g wet wt) 
[Botker et al., 1994; Opie, 1991] and it has a relatively rapid turnover rate 
[Henning et al., 1996]. Glycogen concentrations can be increased by the 
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elevated supply of substrate and/or hyperinsulinaemia [Kruszynska et al., 
1991; Laughlin et al., 1994; Stanley et al., 1997 (a)]. Adrenergic stimulation 
(leading to increased cAMP and Ca2+), a drop in ATP content and a rise in 
inorganic phosphate, which occur with ischaemia or intense exercise 
[Goldfarb et al., 1986; Hue et al., 1995; Stanley et al., 1997 (a)] are all 
activators of glycogenolysis. 
 
5.3.3 Ketone body metabolism 
Under normal physiological conditions, the arterial plasma concentration of 
ketones (3-β-hydroxybutyrate and acetoacetate) is generally very low, which 
makes it a minor substrate for the myocardium. However, during starvation or 
poorly controlled diabetes the hepatic synthesis of 3-β-hydroxybutyrate and 
acetoacetate increases. This leads to elevated plasma ketone body 
concentrations and ketones becoming a major substrate for the heart 
[Avogaro et al., 1990; Stanley et al., 2005]. The myocardium of diabetic 
patients have a high rate of β-hydroxybutyrate uptake and fairly low rates of 
fatty acid uptake [Hall et al., 1996], which suggests that in diabetic patients 
elevated plasma ketone concentrations act to inhibit fatty acid uptake and 
oxidation [Hasselbaink et al., 2003].  
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Figure 1.3: Schematic depiction of myocardial metabolism under conditions of 
(A) normal substrate concentration and (B) increased fatty acid availability. (A) 
Glucose is utilized by the myocardium in the form of G-6-P and processed in one of 
two ways: it is either stored as glycogen (which is also an additional source of G-6-P) 
or utilized in the process of glycolysis. The pyruvate formed during glycolysis can 
either be converted to lactate or decarboxylated to acetyl-CoA. Acetyl-CoA is used by 
the TCA cycle and NADH and FADH2 produced, which leads to ATP formation (from 
ADP+Pi). FFA enters the cardiomyocyte where it is converted to acyl-CoA. Due to the 
mitochondia not being permeable to long-chain acyl-CoA, it is transferred to the 
matrix by a carnitine-dependent transport system. The acylcarnitine is converted by 
CPT-1 and enters the mitochondria where β-oxidation occurs. (B) Increased level of 
FFA availability results in (1) high rate of FFA uptake and oxidation, which inhibits the 
PI3K/PKB/Akt pathway, leading to the development of insulin resistance; (2) 
inhibition of PDH, resulting in decreased glucose oxidation and (3) overexpression of 
PGCα/β and PPARα/β, which results in fatty acid oxidation. Adapted from Chess and 
Stanley (2008). FATP: Fatty acid transporter; G-6-P: glucose-6-phosphate; CPT-1: 
carnitine palmitoyltransferase I; NADH: nicotinamide adenine dinucleotide; FADH2: 
flavin adenine dinucleotide; ATP: adenosine triphosphate; ADP: adenosine 
diphosphate; IR: insulin receptor; PDH: pyruvate dehydrogenase; PGC-1: 
peroxisome proliferator-activated receptor gamma coactivator 1; PPAR: proliferator 
activated receptor 
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6. CELLULAR EFFECTS OF ISCHAEMIA/REPERFUSION LEADING TO 
CELLULAR INJURY 
Damage incurred during myocardial ischaemia results from various factors 
that include the duration of ischaemia, oxygen demand by cardiomyocytes at 
the time of ischaemia and the degree of blood flow to the ischaemic area. 
Importantly, myocardial cell injury may not only be derived from the ischaemic 
incident itself, but also from detrimental effects that occur during the 
restoration of blood flow after the ischaemic incident. In the following sections 
the processes involved in ischaemia and reperfusion will be discussed. Figure 
1.4 (page 39) is a schematic representation of the major cellular effects of 
ischaemia and reperfusion, which lead to irreversible forms of injury. 
 
6.1 During ischaemia 
During ischaemia, substantial changes occur in cardiac energy metabolism, 
as a consequence of reduced availability of molecular oxygen and metabolic 
substrates. A number of these metabolic changes are beneficial and may help 
the heart adapt to the ischaemic condition. However, most of these changes 
are maladaptive and contribute to the harshness of the ischaemic injury 
leading to cell death and contractile dysfunction [Rosano, 2008, Opie 1998].  
The chain of events occurring during ischaemia is thought to be as follows: 
the lack of oxygen and metabolic substrates, lead to the dysfunction of 
mitochondrial metabolism, causing reduced aerobic formation (oxidative 
phosphorylation) of ATP [Hoffmeister et al., 1986; Stanley et al., 1997 (b); 
Liedtke, 1981]. This in turn triggers anaerobic glycolysis and disrupts normal 
cardiac cell function [Stanley, 1997 (a); Opie, 1998]. The first, short-term, 
defence of the heart is to achieve a new balance between the oxygen demand 
and supply by a combination of downregulation of contraction and aerobic 
energy production [Opie, 1998; Hochachka et al., 1996]. Glycolysis can 
provide limited amounts of energy in the absence of oxygen.  
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The pyruvate, produced by glycolysis during ischaemia, is not so promptly 
oxidized in the mitochondria, leading to a high rate conversion of pyruvate to 
lactate in the cytosol and, in turn, a rise in tissue lactate content. Cellular 
homeostasis is dramatically disrupted when the ischaemic myocardium 
switches from the normal lactate uptake from the blood to the production 
thereof. Thus, anaerobic metabolism is linked with intracellular accumulation 
of inorganic phosphate, lactate and H+, which leads to the fall in intracellular 
pH and a reduction in contractile work.   
The SR Ca2+ uptake mechanisms are impaired due to the lack of ATP, which 
leads to the accumulation of intracellular Ca2+ [Gross et al., 1999]. The fall in 
intracellular pH has numerous negative effects on the ability of cardiac muscle 
to maintain Ca2+ homeostasis and use the energy released from the 
breakdown of ATP to perform contractile work. This implies that, at low pH, for 
a given rate of ATP synthesis, more of the energy released from the 
breakdown of ATP contributes to the mechanism of regulating Ca2+ content in 
the cytosol and less to contractile work. Another negative consequence of 
ischaemia is the activation of the sodium-hydrogen exchanger (NHE) by 
intracellular acidosis, which leads to the accumulation of intracellular Na+. This 
Na+ overload is aggravated by inhibition of the sodium pump due to ATP 
depletion (refer to Figure 1.4A). These increased concentrations of solutes 
result in osmotic swelling that may cause sarcolemmal disruption. The extent 
of damage, such as the irreversible injury due to ischaemia, is time-
dependent. Thus, the unrelieved lack of oxygen and metabolites will result in 
the pathological features of cell death. 
 
6.2 During reperfusion 
The view of the past decades was that the process of cell death occurred 
largely during ischaemia, as a result of the manifold consequences of ATP 
depletion. The hypothesis was that reperfusion is essential to restore ATP 
synthesis and so doing, to salvage those cells uninjured or reversibly injured 
by ischaemia. Currently, some researchers believe that all injury develops 
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during the ischaemic period, whereas others argue that reperfusion extends 
tissue injury. This phenomenon of “reperfusion injury” has been a subject of 
debate for the past three decades.  
During reperfusion, the sudden reintroduction of oxygen and metabolites 
causes the reactivation of the mitochondrial electron transport chain. This 
process leads to massive free radical production, namely, reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), in the presence of nitric 
oxide (NO). ROS and RNS cause oxidative and nitrosative damage to cellular 
structures, such as the SR, leading to Ca2+ release. Under conditions of 
restored ATP production, the activity of the Na+/Ca2+ exchanger is restored, 
which leads to the extrusion of Na+ in exchange for Ca2+. In addition, the SR 
Ca2+ release is also accentuated, which leads to increased cytosolic Ca2+ or 
cytosolic Ca2+ overload. The combined effects of Ca2+ accumulation in the 
mitochondrial matrix, ROS/RNS production and the increasing intracellular 
pH, due to H+ washout, favours the formation/opening of the mitochondrial 
permeability transition pore (mPTP), leading to further tissue damage [Opie, 
1998] (refer to Figure 1.4A).  
In the clinical treatment of myocardial infarction, early coronary reperfusion 
has proved to be the only way to limit infarct size [Ostadal, 2009]. There is 
thus no intervention, which is able to limit infarct development in the absence 
of reperfusion. However, the process of reperfusion is associated with further 
biochemical, structural and functional changes. This so-called “reperfusion 
injury” may lead to the death of cardiac myocytes that were still viable 
immediately before myocardial reperfusion. It is common to consider 
ischaemia/reperfusion injury as a composite entity with distinct components of 
injury, since it is true that reperfusion can never take place independently of 
ischeamia. 
There is evidence from animal studies that reperfusion may contribute to 
irreversible cellular injury, leading to apoptosis and necrosis [Nilanjana and 
Tetsuya, 2000; Maulik et al., 1998; Gottlieb et al., 1994]. Oxygen free radicals, 
which are generated upon restoration of blood flow, are the main mediators of 
this reperfusion injury [Eefting et al., 2004]. According to Piper and colleagues 
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(1998) there are three initial causes of immediate reperfusion injury, apart 
from oxygen radicals. They are re-energization, the rapid normalization of 
tissue pH and rapid normalization of tissue osmolality. Data obtained from 
patients with evolving acute myocardial infarction, such as in the Prague 
study, has demonstrated that reperfusion therapy may be beneficial, 
depending on the circumstances, such as how early reperfusion is applied 
[Widimsky et al., 2003].  
In recent years, studies have been devoted to the mPTP and its role in 
reperfusion injury. In the section below this role will be discussed. 
 
6.3 The mitochondrial permeability transition pore (mPTP)  
The mPTP is a voltage-dependent, high-conductance channel located in the 
inner mitochondrial membrane. It is widely accepted that mPTP opening 
contributes to the loss of viability, which is associated with post-ischaemic 
reperfusion. ROS accumulation, pH normalization and a rise in calcium ions, 
create an ideal scenario for mPTP opening [Di Lisa and Bernardi, 2006]. 
Since mPTP inhibition prevents reperfusion injury, this powerful protection, 
which is associated with postconditioning, could be attributed to a decreased 
probability of mPTP opening [Halestrap et al., 2004].  
According to the current knowledge of ischaemia/reperfusion injury and 
cardioprotection, the key determinant of cell death or survival is the opening or 
closing of the mPTP during reperfusion. For the past few decades it has been 
accepted that the mPTP is a proteinaceous complex comprising mainly of the 
voltage-dependent anion channel (VDAC), adenine nucleotide translocase 
(ANT) and cyclophilin D (CyP-D) [Halestrap and Brenner, 2003; Bernardi et 
al., 2006]. However, recent evidence strongly opposes this notion. Based 
upon genetic deletion of ANT, VDAC and CyP-D [Baines et al., 2005; Baines 
et al., 2007; Kokoszka et al., 2004; Krauskopf et al., 2006] it appears that what 
were thought to be essential pore components are probably mPTP regulatory 
elements that are not required for pore formation [Juhasova et al., 2008]. The 
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exact molecular composition of the pore is currently unknown and the subject 
of intense debate.  
The mPTP acts as a voltage-dependent channel and is closed under normal 
physiological conditions when the inner membrane is impermeable to most 
solutes. However, under conditions of stress, the pore converts to an open 
state in the inner membrane that results in the loss of membrane 
impermeabililty and collapse of mitochondrial membrane potential and the 
subsequent release of cytochrome C. This occurence of mPTP opening 
during myocardial ischaemia/reperfusion and its contribution to 
ischaemia/reperfusion injury have been studied extensively during the last 
twenty years [Crompton et al., 1987; Duchen et al., 1993; Lemasters et al., 
1997; Halestrap et al., 1998; Di Lisa et al., 2001; Halestrap et al., 2004; Di 
Lisa and Bernardi, 2006]. The exact mechanisms initiating apoptosis are still 
unknown. However, it seems likely that the opening of the mPTP during 
reperfusion (not during but after ischaemia) serves as a key mechanism of cell 
death to produce a pattern of reperfusion-induced necrosis [Crompton, 1999; 
Hajno´czky et al., 2000; Bishopric et al., 2001; Di Lisa et al., 2001; Pacher and 
Hajno´czky, 2001; Halestrap et al., 2004, Ferdinandy, 2007].  
The current hypothesis is that specific manipulation during reperfusion of 
conditions that inhibit mPTP opening offers the potential to attenuate cell 
death through cardioprotective strategies. Thus, agents given at reperfusion 
may protect through a common mechanism of attenuating mPTP opening in 
early reperfusion. The concept that protective intervention can be used after 
the onset of ischaemia is thus receiving increasing attention and might be 
exploited in clinical settings [Piot et al., 2008]. 
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Figure 1.4: Major cellular effects of ischaemia and reperfusion leading to 
irreversible forms of injury. (A) During ischemia, reduced availability of molecular 
O2 and metabolic substrates results in a deficit of high-energy phosphates. SR Ca2+ 
uptake mechanisms are impaired leading to intracellular Ca2+ accumulation. 
Anaerobic metabolism is associated with intracellular accumulation of inorganic 
phosphate, lactate and H+. Activation of the NHE by intracellular acidosis leads to 
accumulation of intracellular Na+. This Na+ overload is exacerbated by inhibition of 
the sodium pump due to ATP depletion. Increasing intracellular concentrations of 
solutes results in osmotic swelling. The process of irreversible injury is time-
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dependent and, in unrelieved ischemia, will result in the pathological features of 
necrosis. (B) The sudden reintroduction of molecular oxygen causes re-energization 
of mitochondria and reactivation of the electron transport chain with massive 
production of ROS, which may stimulate further ROS production (ROSinduced ROS 
release) and generation of RNS in the presence of NO. ROS/RNS cause oxidative 
and nitrosative damage to cellular structures, including the SR leading to Ca2+ 
release. Also, under conditions of restored ATP production, the activity of the 
Na+/Ca2+ exchanger is restored, leading to the extrusion of Na+ in exchange for Ca2+, 
and SR Ca2+ release is further accentuated by restoration of ATP leading to cytosolic 
Ca2+ overload. The combined effects of Ca2+ accumulation in the mitochondrial 
matrix, ROS/RNS, and increasing intracellular pH due to H+ washout favour the 
opening of the mPTP. The precise rate of injury or mode of cell death during 
reperfusion will be determined by the severity of changes during ischemia as well as 
by the extent of sarcolemmal fragility and disruption, which may be further 
exacerbated during reperfusion by further osmotic swelling and protease activity. 
Adapted from Fernandandy (2007).SR: sarcoplasmic reticulum; NHE: sodium-
hydrogen exchanger; ROS: reactive oxygen species; RNS: reactive nitrogen species; 
mPTP:  mitochondrial permeability transition pore 
 
6.4 Cellular injury and infarction 
At the onset of ischaemia, rapid structural changes occur in the myocardium. 
These may be either reversible or irreversible changes. These changes are 
considered reversible alterations if reperfusion of the tissue occurs rapidly. 
However, if this ischaemic incident lasts more than 20 to 30 min (in a rat 
heart), the result is irreversible tissue injury that is ultimately characterized by 
cell death [Reimer and Jennings, 1979; Jennings et al., 1981]. Numerous 
factors that affect the onset and extent of irreversible injury in experimental 
models have been identified. Amongst these factors are the size of the area at 
risk of infarction, the duration of ischaemia [Reimer and Jennings, 1979; 
Ytrehus et al., 1994], the degree of blood flow or residual flow through the 
infarct-related artery [Reimer and Jennings, 1979], myocardial temperature 
[Miki et al., 1998] and heart rate may contribute to the rate of development of 
irreversible injury [Schulz et al., 1995].  
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In the clinical setup, mortality related to myocardial infarction is closely related 
to the duration of the coronary occlusion. In the literature, it is well 
documented that certain cells subjected to ischaemia/reperfusion display 
signs of apoptosis. However, there is controversy as to the extent of apoptosis 
in ischaemia/reperfusion injury and the relationships between apoptosis and 
necrosis [Kajstura et al., 1996; Misao et al., 1996; Olivetti et al., 1996; Saraste 
et al., 1997; Baliga, 2001; Bishopric et al., 2001].  
 
6.4.1 Necrosis and apoptosis  
In the human heart, cardiac failure is depicted by the progressive death of 
cardiomyocytes [Olivetti et al., 1997]. According to the literature, there are two 
general mechanisms responsible for myocyte cell death during myocardial 
ischaemia/reperfusion, i.e. necrosis and apoptosis [Majno and Joris, 1995]. 
Up to about a decade ago, it was believed that all adult cardiomyocyte death 
was caused by necrosis, however, Narula and colleagues (1996) and Olivetti 
and colleagues (1997) provided some of the first evidence that apoptosis 
occurs in the myocardium of patients with end-stage dilated cardiomyopathy.  
Cardiac cells undergoing necrosis show characteristically different 
morphological and biological features compared to those undergoing 
apoptosis. Necrosis is generally a rapidly occurring form of cell death that may 
trigger a significant inflammatory response. Changes include severe cellular 
and organelle swelling, denaturation and coagulation of cytoplasmic proteins 
and breakdown of cell organelles. In contrast, apoptosis is an energy-
dependent process in which cell death follows a genetically controlled 
programmed sequence of events. Its main morphological features are: loss of 
cell membrane phospholipid asymmetry, condensation of chromatin and 
formation of cytoplasmic blebs. During the end stage of apoptosis, cellular 
fragments form into membrane-bound apoptotic bodies that confine 
intracellular content and prevent initiation of an inflammatory response 
[Haunstetter and Izumo, 1998, 2000; Bartling et al., 1998; MacLellan and 
Schneider, 1997].  
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It might be possible that both apoptosis and necrosis are activated in the 
myocardium and may thus co-determine the final degree of lethal myocardial 
injury after ischaemia and reperfusion [Piper et al., 1998; James, 1998]. 
 
6.4.2 Cellular survival: The role of PI3K/PKB/Akt pathway 
PI3K/PKB/Akt signaling cascade is seen as the main prosurvival pathway 
[Duronio, 2008; Baines et al., 1999]. The PI3K/PKB/Akt pathway appears to 
both negatively regulate factors that promote the expression of death genes 
and positively regulate factors that induce survival [Duronio, 2008; Parcellier et 
al., 2008; Barthwal et al., 2003; Brunet et al., 1999].  
Apoptosis, which was discussed in section 6.4 (page 40), refers to a complex 
set of events occurring within a cell that eventually leads to cellular destruction 
initiated by proteolytic enzymes known as caspases [Earnshaw et al., 1999; 
Budihardjo et al., 1999]. The ability of all cells to undergo apoptosis is 
suppressed by survival signals induced by factors within their immediate 
environment. PKB/Akt is crucial in cell survival. This can be seen in studies 
done where dominant negative alleles of PKB/Akt reduced the ability of growth 
factors and other stimuli to maintain cell survival, whereas activated PKB/Akt 
or over-expression of the wild-type, could rescue cells from apoptosis induced 
by various stress signals [Kennedy et al., 1997; Kulik et al., 1997].  
Activated PKB/Akt has the ability to phosphorylate two classes of substrates 
that are known to be implicated in the life/death cycle of cells: (1) the anti-
apoptotic substrates which, when phosphorylated, are activated and 
contribute to survival and (2) the pro-apoptotic substrates which, when 
phosphorylated [Franke et al., 2003], become inactive and cell death can thus 
not occur. The PI3K/PKB/Akt pathway has been shown to play a vital role in 
myocardial protection against ischaemia/reperfusion injury in all species 
studied, both in vivo and in vitro [Hausenloy and Yellon, 2004; Mocanu and 
Yellon; 2007]. 
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6.4.3 Autophagic cell death 
During the past few years, another form of cell death, autophagic cell death, 
has drawn considerable attention [Edinger and Thompson, 2004]. Autophagy 
is a catabolic process involving the degradation of the cell's own components 
through lysosomal mechanisms. Autophagy has been recognised in a number 
of cardiac disorders, such as ischaemia and cardiac hypertrophy. This 
mechanism seems to help maintain a balance between the synthesis, 
degradation and subsequent recycling of cellular products [Goswanni and 
Das, 2006]. Thus, stimulation of autophagy may have cardioprotective effects. 
However, unlike in apoptosis, in which families of cysteine proteases and a 
number of other regulatory proteins have been identified, the mechanism of 
autophagic cell death remains unclear. 
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CHAPTER 2 
Materials and Methods 
 
2.1 Animal care 
Throughout this study age and weight matched male, Wistar rats were used. 
All animals were housed in a temperature-controlled room (22 °C – 24 °C) 
and kept on a 12-hour light/dark cycle. Animals had free access to standard 
laboratory rat chow and water until the time of experimentation. The animals 
were housed at the University of Stellenbosch Central Research Facility, 
receiving humane care in accordance with the principles of the “Guide for care 
and the use of laboratory animals” published by the US National Institutes of 
Health (NIH publication no 80 - 23, revised 1985). The project was approved 
by the Ethics committee of the Faculty of Health Sciences, University of 
Stellenbosch. Ethics approval numbers are P05/11/013 for antidiabetic 
research and P07/11/020 for cardiovascular research.
 
2.2 Animal models 
2.2.1 Streptozotocin-induced type 1 diabetes rat model 
As soon as the rats reached the desired weight (230 – 250 g), they were 
randomly divided into two groups: control (n = 16) and diabetic (n = 24). Type 
1 diabetes was induced with a single, intra-peritoneal injection of freshly 
prepared streptozotocin (STZ) (Sigma Aldrich, St Louis, MO) in citrate buffer 
(pH 4.5) and injected at 40 mg/kg body weight. The control animals were 
injected with buffer. This model has previously been shown to result in a 
graded diabetic response, where the animals retain a portion of their 
pancreatic function and do not suffer complete β-cell ablation [Arison and 
Fendale, 1967; Junod et al., 1969; Brondum et al., 2005].   
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One week post-STZ injection the animals were fasted overnight, blood 
collected via a once-off tail prick and plasma glucose concentration measured 
using a glucometer (GlucoPlusTM, Montreal, Canada). Animals with fasting 
blood glucose levels of > 10 mmol/L were considered type 1 diabetic. From 
the 24 original animals, 9 animals had blood glucose levels exceeding 10 
mmol/L. The 15 animals with lower blood glucose levels were excluded from 
the study. For both the control as well as the diabetic group, half of the 
animals (i.e control: n = 8 and diabetic: n = 5) were placed on DiaviteTM 
treatment (25 mg/kg/day). This treatment continued for 8 weeks (refer to 
Figure 2.1 for a schematic representation of division into groups and Figure 
2.2 for a diagram outlining the time-line of STZ experiment).  
 
 
 
 
 
 
 
 
Male Wistar rats
(n = 40) 
 
Control 
(n = 16) 
 
Diabetic 
(n = 24) 
 
Control 
(n = 8) 
Control + 
DiaviteTM 
(n = 8) 
 
Diabetic 
(n = 4) 
Diabetic + 
DiaviteTM  
(n = 5) 
 
Figure 2.1: Schematic representation of the division into groups of STZ-
induced type 1 diabetes animals 
 
DiaviteTM was weighed daily for each animal in the treatment group and set in 
a mixture of commercially available gelatine/ jelly cubes of 1 ml volume. This 
was fed to each animal, individually, to ensure absolute compliance and dose 
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control. Dosages of DiaviteTM were calculated based on the normal daily 
dosage prescribed by the producers, which is 7 g per adult. To determine the 
dose for rats, we made our calculations assuming the average daily weight of 
an individual as 70 kg. 
After an overnight fasting period (8 weeks after the onset of treatment), the 
animals were weighed and then anaesthetized with an intra-peritoneal 
injection of sodium pentobarbital (80 mg/kg). The animals were continually 
monitored until total loss of consciousness was reached, as indicated by a 
total lack of response after a foot pinch. The hearts were then removed, snap-
frozen and stored in liquid nitrogen for further analysis. Blood samples were 
collected from the abdominal cavity and subsequently subjected to 
centrifugation (microcentrifuge at 1000 g at 4°C for 10 min), whereafter the 
plasma aliquots were stored at −80 °C until assays were done. Serum insulin 
levels were determined via a Coat-A-Count® Radioimmunoassay (RIA) kit 
(Siemens Medical Solutions Diagnostics, Los Angeles, CA). The pancreata 
were also removed, stored in 4% phosphate buffered formalderhyde and sent 
for pancreatic analysis at the Medical Research Council (MRC) in Cape Town, 
South Africa. Histological data to be discussed in section 2.7 on page 59.  
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animals were anaesthetized and:
• Body weight measured
• Hearts removed for further  
analysis
• Blood samples collected for 
serum insulin and blood glucose 
determination
56 DAYS (8 WEEK) DiaviteTM treatment
 
 
 
 
 
 
 
 
Figure 2.2: Diagram outlining the time-line of STZ experiment. (A) control and 
(B) diabetic group    
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2.2.2 Diet-induced obese insulin resistant rat model 
2.2.2.1 Special diets 
We utilized a model of diet-induced-obesity (DIO) [Pickavance et al., 1999] 
with the concurrent development of insulin resistance. This model is one of 
hyperphagia-induced obesity and it has been characterized in our laboratory 
and shown to be physiologically relevant and comparable to the human 
equivalent of insulin resistance as a result of obesity [Du Toit et al., 2005]. In 
the DIO model, the diet of the adult rats are changed similarly to the changes 
experienced by humans, changing from the more frugal, rural diet to a 
Westernized, fast food diet. This high caloric diet consists of normal rat chow 
supplemented with sucrose and condensed milk, resulting in an elevated fat 
and carbohydrate intake coupled to a low protein intake (refer to Table 2.1 for 
the nutritional composition of the control versus DIO diet).  
The control group of animals received normal unsupplemented rat chow.  
 
Table 2.1 Macronutrient composition (% total energy value) of diet consumed 
by control versus diet-induced obese (DIO) animals 
 Control DIO 
Carbohydrates 60% 65% 
Fat 10% 16% 
Protein 30% 19% 
 371 ± 18 kJ/day 570 ± 23 kJ/day 
 
2.2.2.2 Division into groups 
Male Wistar rats weighing in at 180 - 200 g were randomly divided into two 
groups: control (n = 45) and DIO (n = 45) and placed on their corresponding 
diets for a period of 8, 12 and 16 weeks respectively (refer to Figure 2.2 for 
schematic representation of division into groups as well as sample size). The 
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control group received the standard rat chow and the DIO group received the 
high caloric diet. The 8-week animals were not placed on the DiaviteTM 
treatment. However, the 12 and 16-week animals was on their different diets 
(control and DIO respectively) for 8 weeks, where after half of each group (i.e. 
n = 9) was placed on the DiaviteTM (25 mg/kg/day) treatment for the remaining 
4 and 8 weeks, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Male Wistar 
rats 
(n = 90) 
Control 
(n = 45) 
DIO 
(n = 45) 
 
Control 
(n = 27) 
 
Control + 
DiaviteTM 
(n = 18) 
DIO 
(n = 27) 
 
DIO +  
DiaviteTM  
(n = 18) 
8 weeks 
(n = 9) 
12 weeks 
(n = 9) 
16 weeks 
(n = 9) 
 
12 weeks 
(n = 9) 
 
16 weeks 
(n = 9) 
8 weeks 
(n = 9) 
12 weeks 
(n = 9) 
16 weeks 
(n = 9) 
 
 
12 weeks 
(n = 9) 
16 weeks 
(n = 9) 
 
Figure 2.3: Schematic representation of the division into groups of DIO insulin 
resistant animals. DIO: diet-induced obesity 
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2.3 Isolated rat heart perfusion technique 
2.3.1 Retrograde perfusion (Balloon model) 
Following the 8, 12 and 16 week period on the feeding programme the rats 
were anaesthetized by intra-peritoneal injection of sodium pentobarbital at a 
dose of 80 mg/kg. Rats were continually monitored until total loss of 
consciousness was reached, as indicated by a total lack of response after a 
foot pinch. Body weights were recorded was soon as the animals lost 
consciousness. At the point of sacrifice, non-fasting blood was collected for 
blood glucose and serum insulin measurements, which was determined by 
means of a glucometer (GlucoPlusTM) and a Coat-A-Count® 
Radioimmunoassay (RIA) kit (method discussed in section 2.8.2 below), 
respectively. In addition, intra-peritoneal fat was removed and the weight 
thereof recorded.  
The hearts were excised and placed in ice-cold Krebs-Henseleit buffer before 
being mounted on a Langendorff perfusion apparatus via the aortic cannula. 
Retrograde perfusion was resumed within 1 to 2 minutes after excision of the 
heart, during which all excess adipose and connective tissue were trimmed 
off. Nutrient-rich, Krebs-Henseleit buffer was used as perfusate and it 
contained: 119 mM NaCl; 24.9 mM NaHCO3; 4.74 mM KCl; 1.2 mM KH2PO4; 
0.6 mM MgSO4.7H2O; 0.6 mM Na2SO4; 1.25 mM CaCl2.2H2O and 10 mM 
glucose. All these chemicals were purchased at Merck (Pty) Ltd - South 
Africa. The buffer (pH = 7.4) was oxygenated by gassing it with 95% O2/ 5% 
CO2. Pressure (100 cmH2O) and temperature (37 ± 1 °C) were maintained 
throughout the experiment and a temperature probe, which was inserted into 
the coronary sinus, continuously monitored the change in temperature. The 
pressure of the solution caused the aortic valve to shut and the perfusate to 
be forced into the coronary vessels. This allowed the heart to beat for several 
hours. In this model, a water-filled latex balloon coupled to a pressure 
transducer (Viggo Spectromed) was inserted into the left ventricle of the heart, 
to measure changes in developed pressure. This technique allowed the 
examination of cardiac contractile strength and performance, heart rate and 
vascular effects without the neuronal and hormonal complications of an intact 
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animal model. Thus, the functional performance, before and after the 
ischaemic insult, was computed in terms of the heart rate (HR), left ventricular 
developed pressure (LVDP: left ventricular systolic pressure – left ventricular 
diastolic pressure) as well as the rate pressure product (RPP). The RPP is 
calculated as the cumulative effect of the change in left ventricular developed 
pressure and the heart rate (LVDP x HR). The changes in these parameters 
were continually recorded on a computerized system for the entire duration of 
the experiment. 
The perfusion protocol of the isolated rat hearts consisted of a 30 min 
stabilization period, which was followed by a 35 min regional ischaemic 
incident and completed with a 120 min reperfusion period. All phases taking 
place at a constant temperature and pressure. 
 
 
 
Stabilization
Regional 
 ischaemia Reperfusion 
30 min 35 min 120 min 
 
Figure 2.4: General perfusion protocol  
 
2.3.2 Application of regional ischaemia 
Regional ischaemia is used when infarct size needs to be determined. A silk 
suture was inserted around the left coronary artery, in such a way that it could 
be loosened to allow for reperfusion when needed. Ischaemia, which 
represents a heart attack, was induced by occluding the left anterior 
descending artery (for a period of 35 min) by tightening the suture. The 
successful occlusion was confirmed by a reduction in coronary flow. Following 
the 35 min period of regional ischaemia, the snare on the coronary artery was 
released and reperfusion was allowed for 120 min. 
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2.3.3 Infarct size determination 
At the end of the experimental protocol, the silk suture, around the coronary 
artery, was tightened securely and 5 ml 0.5% Evans Blue suspension slowly 
infused into the aorta. This was done to delineate the area at risk of infarction.  
The hearts were removed from the system and frozen overnight before being 
sectioned into ± 2 mm thick slices. After defrosting, the slices were stained by 
incubation at room temperature for 15 min in 1% w/v triphenyltetrazolium 
chloride (TTC) in phosphate buffer (pH 7.4), which is a well-recognized dye 
technique. TTC staining results in the viable tissue staining a “brick-red” 
colour, as the tetrazolium salts react with the dehydrogenases in the cells and 
the infarcted tissue stains a pale-white since they lack the enzymes with which 
the TTC reacts [Han and colleagues, 2008]. Slices were then fixed in 10% v/v 
formaldehyde solution for 2 hours to stop all chemical reactions and enhance 
the contrast between stained viable tissue and unstained necrotic tissue. The 
blue area represents the viable and undamaged tissue, the white area 
presents the unstained, necrotic tissue and the “brick-red” area represents the 
area at risk. Each slice was mounted between two plates of transparent 
perspex of a known distance apart and traced onto a transparent film. The 
images were imported into the UTHSCSA ImageTool graphics package 
(University of Texas Health Science Center at San Antonio, Texas) and the 
area at risk of infarction (AR) as well as the actual size of infarcted tissue 
(IFS) determined using planimetry. The UTHSCSA ImageTool graphics 
package is available from the internet at 
http://ddsdx.uthscsa.edu/dig/itdesc.html. The infarct size was expressed as 
the percentage of the risk zone infarcted. 
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2.4 Western blot analysis 
2.4.1 Sample preparation 
Separate groups of animals were used for the determination of infarct size 
and protein expression. Animals were placed on the same control and DIO 
diet (with and without DiaviteTM), as described in section 2.2.2.1 of Materials 
and Methods for a period of 16 weeks. At the end of the feeding programme 
the animals were sedated as described in section 2.3.1 of Materials and 
Methods, their hearts isolated, washed in ice-cold Krebs-Henseleit buffer and 
the ventricles snap-frozen using Wollenberger tongs, pre-cooled in liquid 
nitrogen. After the hearts had been snap-frozen they were submerged into 
and stored in liquid nitrogen until later use. Protein expression determination 
and quantification analysis were done as follows: 
 
2.4.2 Protein extraction 
The proteins of interest were extracted from the cardiac tissue by means of a 
lysis buffer that contained: 2 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 
150 mM NaCl, 1 mM β-glycerophosphate, 2.5 mM tertasodiumpyrophosphate, 
1 mM sodium orthovanadate (Na3VO4), 1% Triton X-100, 10 µg/ml leupeptin, 
10 µg/ml aprotinin and 50 µg/ml phenylmethyl sulfonyl fluoride (PMSF). 
Frozen heart tissue (± 200 mg) (section 2.4.1) was pulverized and 
homogenized, using a Polytron PT-10 homogenizer (2 x 4 sec, setting 4) in 
0.7 ml cold lysis buffer. The homogenate was left to stand on ice for 15 
minutes to allow digestive processes to take place. After 15 minutes, the 
homogenate was transferred to Eppendorf tubes and samples were subjected 
to centrifugation at 1000 g for 10 min at 4 °C, where after the supernatant was 
collected in a separate set of Eppendorf tubes.  
The protein content of each sample was measured by means of the Bradford 
(1976) protein method. Bradford solution contained: 0.6 mM Coomassie 
Brilliant Blue G-250, 95% ethanol and 85% (w/v) phosphoric acid. Colour 
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development (absorbance) was read at 595 nm against a blank and sample 
values were determined from a standard curve generated from bovine serum 
albumin (BSA) of known concentrations. This sensitive method is suitable for 
measuring microgram quantities of proteins. The supernatant was then diluted 
in Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptothanol, 
0.0004% bromphenol blue and 0.125 M Tris-HCl) to contain equal amounts of 
protein per volume unit [Laemmli, 1970]. The samples was boiled for 5 min 
and aliquots stored at -80 °C. 
 
2.4.3 Protein separation 
All stored aliquots were boiled for 5 min and samples were subjected to 
centrifugation at 15000 rpm for 2 min. Of each sample, 60 µg was loaded in a 
stacking polyacrylamide gel and separated according to their molecular 
weights by subjection to a sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) in running buffer (refer to Table 2.2 for the 
tabular representation of the Western blot analysis). The running buffer 
contained: 50 mM Tris, 384 mM glycine and 1% SDS. A standard Bio-RAD 
Mini-Protean III system was used. A protein ladder, obtained from Fermentas 
Life Sciences, was utilized as marker to identify the molecular weights of the 
proteins of interest.  
The proteins separated within the SDS-gel were then transferred to 
polyvinylidene fluoride (PVDF) membranes (ImmobilonTM P, Millipore) with an 
applied electrical current of 200 V for 1 hour, in a tank filled with transfer 
buffer. The transfer buffer consisted of 25 mM Tris, 192 mM glycine and 20% 
methanol. At the end of the transfer period, the membranes were immersed in 
fresh methanol and left to air dry. This was done so that the membranes could 
be stained with 5% Ponçeau Red in acetic acid (reversible protein stain), for 
visualization of proteins and to confirm whether adequate transfer did in fact 
occur.  
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Once the Ponçeau Red was rinsed off, the non-specific binding sites on the 
membranes were blocked by gently incubating them in fat-free milk, made up 
in a TBS-Tween solution (Tris-buffered saline (TBS) plus 0.1% Tween 20), for 
between 1 and 2 hours, at room temperature on a shaker. At the end of the 
“blocking” period, the membranes were thoroughly washed in the TBS-Tween 
solution. These membranes were then probed with primary antibodies 
directed against: GLUT1, GLUT4, total and phospho-PKB/Akt (Ser473), total 
and phospho-PTEN (Ser380/Thr382/Tyr383), total and phospho-PI3K p85 
(Tyr458)/p55 (Tyr199) and total IRβ and left to incubated overnight at 4 °C. The 
antibodies were diluted as stated in Table 2.2. 
 
2.4.4 Immunodetection of protein 
After the overnight primary antibody incubation, the membranes were 
thoroughly washed in TBS/Tween and incubated in an anti-rabbit 
immunoglobulin G, Horseradish-peroxidase conjugated secondary antibody 
(from donkey), purchased at Amersham life Science (Sandton, 
Johannesburg), for 1 hour at room temperature on a shaker. The secondary 
antibody was diluted as stated in Table 2.2. This conjugated antibody now 
bound to the already bound primary antibody. To remove the excess 
secondary antibody, the membranes were washed extensively in TBS/Tween 
and kept moist.  
Proteins were visualized by covering the membrane with enhanced 
chemiluminescence (ECL) detection reagent (from Amersham life Science, 
Sandton, Johannesburg) for 1 minute and then exposing it to an 
autoradiography film (Hyperfilm ECL, RPN 2103). The Horseradish-
peroxidase reacts with the detection reagent in a luminescence reaction and 
light emission that results, is captured on the radiography film. Band 
intensities were then densitometrically quantified using UN-SCAN-ITTM 
(version 5.1, Silkscience) image analysis software.  
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For comparison purposes, samples from negative control hearts were always 
included in each blot and used for normalization of the unknown samples (i.e 
calculation of the ratio between the sample and negative control). Normalized 
data was expressed in arbitrary units (AU).  
In all instances the membranes were stripped, by incubating for 5 min in 0.2 M 
NaOH and reblotted with antibody against β-tubulin (1:1000, Cell Signaling 
Technology, Beverly, MA) to verify the uniformity of protein load and the 
transfer efficiency across the test samples. 
 
Table 2.2: Tabular representation of Western blot analysis 
Protein  Molecular 
weight 
Polyacrylamide 
stacking gel  
Seperation 
gel 
Blocking 
solution 
dilutions 
Primary 
antibody 
dilutions 
Secondary 
antibody 
dilutions 
GLUT1  ± 55 kd 10% 4% 2.5% milk in 
TBS/Tween  
20µl/5ml in 
1% milk 
3µl/20ml in 
2.5% milk 
GLUT4 ± 45 kd 10% 4% 5% milk in 
TBS/Tween 
5µl/5ml in 
TBS/Tween 
5µl/20ml in 
2.5% milk 
PKB ± 63 kd 10% 4% 5% milk in 
TBS/Tween 
5µl/5ml in 
TBS/Tween 
5µl/20ml in 
2.5% milk 
PTEN ± 54 kd 10% 4% 5% milk in 
TBS/Tween 
5µl/5ml in 
TBS/Tween 
5µl/20ml in 
2.5% milk 
p85 ± 85 kd 10% 4% 5% milk in 
TBS/Tween 
5µl/5ml in 
TBS/Tween 
5µl/20ml in 
2.5% milk 
IRβ ± 98 kd 7.5% 4% 5% milk in 
TBS/Tween 
5µl/5ml in 
TBS/Tween 
5µl/20ml in 
2.5% milk 
 
2.5 Preparation of ventricular cardiac myocytes 
Adult ventricular cardiomyocytes were prepared from a separate group of 16 
week treated animals. Cardiomyocytes were isolated from animals on the DIO 
as well as the control diet, with or without DiaviteTM (as described in section 
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2.2.2.2) using isolation methods previously described by Fischer and 
collegues (1991) and subsequently modified in our laboratory [Huisamen et 
al., 2001]. Hearts were excised from fully anaesthetized animals, as described 
in section 2.3.1 and placed in ice-cold Krebs-Henseleit buffer. After isolation, 
hearts were cannulated via the aorta and retrogradely perfused, at a 
temperature of 37 oC, with a calcium free HEPES buffer (“Solution A” 
containing:  6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 
128 mM NaCl, 10 mM HEPES, 5.5 mM D-glucose and 2 mM pyruvate, pH 
7.4) for five minutes to rinse out the blood. The perfusate was continually 
gassed with 100% O2. The next step was perfusion, in a re-circulating fashion, 
with a HEPES digestion buffer (“Solution B” containing: “Solution A” + 0.7% 
fatty acid free BSA + 1 mg/ml collagenase + 18 mM 2,3 butanedione 
monoxime (BDM)) for 15 min. 50 µl of CaCl2 (100 mM) was re-administered at 
20 and again at 25 minutes of total perfusion time, respectively. Successful 
digestion was confirmed after perfusate no longer dripped from the heart, but 
flowed continously. After digestion, hearts were removed from the perfusion 
apparatus and the ventricles carefully removed from atria.  
The ventricular tissue was then gently torn apart and incubated in a post-
digestion buffer (50 ml “Solution C” containing: 50% of “Solution A” + 50% of 
“Solution B” + 1% BSA + 1% fatty acid free BSA + 0.2 mM CaCl2) for 15 min 
at 37 oC in a shaking waterbath (180 strokes/min). A step-wise re-
administration of calcium for a period of 5 minutes followed until the final 
concentration of 1.25 mM was reached (4 x 100 µl and 1 x 125 µl of 100 mM 
CaCl2). Thereafter, the tissue was filtered through a nylon mesh (200 x 200 
μm) and gently samples were subjected to centrifugation at 100 rpm for 3 min. 
The cell pellet was resuspended in Solution D (“Solution D” containing: 
“Solution A” + 2% fatty acid free BSA + 1.25 mM CaCl2) and the cells allowed 
to settle for 5 min under gravity through the 2% BSA solution into a loose cell 
pellet. Only live, healthy cardiomyocytes will settle. The supernatant, 
containing dead or dying cells, was aspirated and the cell cell pellet obtained 
was resuspended in Solution D and left to stabilize on a slow rotator at room 
temperature for two hours. After the 2 hours, the cells were allowed to settle 
under gravity and the supernatant gently removed. The cells were then 
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washed with Solution E (“Solution E” containing: “Solution A” (minus D-
glucose and pyruvate) + 2.0% fatty acid free BSA + 1.25 mM CaCl2) and 
allowed to settle under gravity, whereafter the supernatant was removed and 
the cell pellet used for 2-deoxy-D-3[H] glucose (2DG) uptake experiments as 
discussed below in section 2.6. 
The HEPES, pyruvate and BDM were all obtained from Sigma-Aldrich (St 
Louis, MO), the D-glucose was obtained from Merck (Pty) Ltd - South Africa, 
the Collagenase Type II was purchased from Worthington Biochemical 
Corporation (Lakewood, NJ) and the BSA was obtained from Roche (Cape 
Town). 
 
2.6 Determination of 2-Deoxy-D-3[H] glucose (2DG) uptake by 
cardiomyocytes 
The cell’s ability to accumulate 2DG was measured as described previously 
[Fischer et al., 1991; Donthi et al., 2000; Huisamen et al., 2001].  
The cardiomyocyte cell pellet (section 2.5) was suspended in an oxygenated 
medium that contained: 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 
mM MgSO4, 128 mM NaCl, 10 mM HEPES, 1.25 mM CaCl2 and 2% fatty acid 
free BSA (pH 7.4). Aliquots (approximately 0.5 mg protein) were assayed in a 
total volume of 750 µl and were left to equilibrate for 15 min in a shaking 
waterbath (180 strokes/minute) at 37 °C, with or without phloretin (400 µM). 
An assay in the presence of phloretin was included to measure non-carrier 
mediated glucose uptake. Cells were then stimulated with or without 1, 10 or 
100 nM insulin for 30 min in duplicate, whereafter they were incubated with 
1.5 μCi/ml 2DG (PerkinElmer, Boston) in a final concentration of 1.8 μM 
deoxyglucose for 30 min, to allow for glucose uptake. The reaction was 
stopped by the addition of 50 μl (final concentration of 400 μM) phloretin in 
order to stop carrier-mediated (GLUT1 and GLUT4) glucose uptake. Following 
a 1 min microfuge at 1000 g, this 2DG containing supernatant was aspirated 
and cells were washed twice with a basic HEPES buffer that contained: 6 mM 
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KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 128 mM NaCl and 
10 mM HEPES. The cell pellet was then dissolved in 0.5 ml of 1 N NaOH at 
70 °C in a water bath for 30 to 40 min; whereafter 0.5 ml of dH2O was added.  
A 50 μl aliquot of cell lysate in 0.5 N NaOH was used for determination of 
protein content by the method of Lowry [Lowry et al., 1951] and in order to 
determine cell-associated radioactivity, the rest of the cell lysate was mixed 
with 3 ml of scintillation fluid and kept overnight in the dark before counting in 
a scintillation counter (Beckman). 2DG uptake was presented as pmol 
2DG/mg protein/30 min.   
For protein content determination by the method of Lowry [Lowry et al., 1951]; 
three BSA protein standards of known concentration [0.238 mg/ml; 0.476 
mg/ml and 0.952 mg/ml] were used and 0.5 N NaOH used as the blank. The 
reaction buffer, which contained 2% Na2CO3, 1% CuSO4.5H2O and 2% NaK+ 
tartrate, was freshly prepared prior to experimentation. The assay was done in 
duplicate and 50 μl of blank, standards and samples were used to perform the 
protein assay. 1 ml of the reaction buffer was added to the blank, standards 
and samples, rapidly vortexed and allowed to stand at room temperature for 
10 min. Afterwards 0.1 ml Folin-Ciocalteu’s phenol reagent (1:2 dilution with 
distelled water) was added, vortexed and permitted to stand for 30 min. This 
resulted in a colour development of which the absorbance was read at 750 nm 
against the blank. The standard curve was used to determine the unknown 
protein concentrations.  
 
2.7 Pancreatic analysis 
The rat pancreata was removed (follows from section 2.2.1 on page 44) and 
fixed in 4% phosphate buffered formaldehyde whereafter it was processed in 
an automatic tissue processor through ascending grades of ethanol, xylene 
and subsequently embedded in paraffin wax. By means of a rotary microtome, 
the pancreas were sectioned into 4 – 6 mm thick slices, mounted onto glass 
slides and placed in an oven for 30 min at 60 C. Following the 30 min, each o
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section was immunolabelled for α-cells with a polyclonal glucagon antibody 
(Dako, Carpinteria, CA) for 30 min at room temperature.  Thereafter, a 
secondary biotinylated anti-rabbit link antibody was applied and positive 
labeling was visualised using the peroxidase diaminobenzidine tetrachloride 
method. This was followed by the immunolabeling of the β-cells, which was 
accomplished with a monoclonal insulin antibody (Sigma ImmunoChemicals, 
St. Louis, MO) overnight at 4 C. Subsequently, a secondary biotinylated anti-
mouse link antibody was utilized and positive labeling was visualised using 
the alkaline phosphatase fuchsin method. The primary antibody was omitted 
in the control samples. All sections were counterstained with Mayers 
haematoxylin for 2 min, air dried and mounted in Entallen .  
o
®
The image analysis system which was used comprised of a Leica DC290 
digital camera that was mounted on an Olympus BX60 light microscope. The 
light microscope was interfaced with a personal computer via Leica Qwin  
Professional Software. All sections of each pancreas were viewed in entirety 
with an x10 objective, the field of view captured and digitized to 768 x 1,024 
pixels. The system was calibrated for the x10 objective, in the X and Y 
direction, using a 
®
micrometric square with dimensions of 50 microns. All tissue 
parameters were measured using a Leica Qwin  routine.  ®
Positive staining was identified by colour segmentation, using RGB 
thresholding. Firstly, the whole section area was identified and measured. 
Thereafter, the islets were visually identified (different stained colours), 
interactively demarcated and their total areas determined.  Subsequently, α-
cell area (brown positive staining) and β-cell area (red positive staining) were 
identified and the areas measured.  All data was exported and analysed using 
Microsoft Excel. Endocrine to exocrine ratios were calculated by dividing the 
total islet area measured by the total tissue area measured. The ratio of β-cell 
to α-cell was calculated by dividing the total β-cell area by the total α-cell area 
measured. β-cells were sized using the following β-cell area parameters: 0 – 
2500 µm2; 2501 - 7500 µm2; 7501 - 12500 µm2; 12501 - 20000 µm2; and > 
20000 µm2. 
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2.8 Biochemical analysis 
2.8.1 Blood sample collection 
After excision of the hearts, blood samples were collected and placed into 
Eppendorf tubes. The samples were subjected to centrifugation for 30 min at 
4 °C and 15000 rpm, serum removed and stored at - 80 °C until biochemical 
analysis was done. 
 
2.8.2 Serum insulin determination: Radioimmunoassay (RIA)  
(Coat-A-Count® Insulin, Diagnostic Products Corporation, LA, USA)  
The blood samples collected at the time of sacrifice (refer to section 2.2.1 on 
page 44 (STZ) and 2.3.1 (DIO) on page 50) were used for serum insulin 
determination.  
The Coat-A-Count Insulin procedure is a solid-phase RIA. 125I-labeled insulin 
and the insulin in the blood sample, competes for sites on the insulin-specific 
antibody. This antibody is immobilized to the wall of the polypropylene tubes. 
Decanting the supernatant from the tubes terminates the competition and 
isolates the antibody bound fraction of the radiolabeled insulin. By counting 
the tubes in the gamma-counter, the presence of insulin in the blood sample 
can be measured. All samples were done in duplictate. 
Prior to the commencement of the assay, all the components of the assay 
were brought to room temperature, as instructed by the manufacturers. 
Uncoated 12 x 74 mm polypropylene tubes were labeled for total count (T) 
and non-specific binding (NSB) respectively. Insulin-antibody coated tubes 
were labeled for standards (refer to Figure 2.5) and serum sample.  
200 μL of the zero calibrator A was pipetted into the NSB and A tubes. 200 μL 
of the remaining calibrator and serum sample were pipetted in the tubes 
prepared (as indicated in Figure 2.5). 1.0 ml of 125I insulin (refer to Table 2.3 
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for the WHO International Reference Preparation (IRP) of Insulin) was added 
to each tube and subsequently vortexed.  
 
 
NSB NSB
1 32 4
200µl zero calibrator
200µl calibrator B
A A B B C C D D E E F F G G
200µl calibrator C
200µl calibrator D
200µl calibrator G
200µl calibrator F
200µl calibrator E
T T
1.0 mL 125I insulin
 
 
 
 
 
 
 
 
Figure 2.5: Schematic representation of tube preparation 
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Table 2.3: Tablular representation of the calibrators and WHO International 
Reference Preparation (IRP) of Insulin (code 66/304) used. 
Calibrator Approximate µIU/ml 1st  IRP 
[code: 66/304] 
A 0 
B 5 
C 15 
D 50 
E 100 
F 200 
G 350 
 
Samples were incubated for 18 to 24 hours at room temperature and 
decanted thoroughly. This was done by placing each tube (except the total 
count tube) in a foam decanting rack and allowing the tubes to drain for 2 to 3 
minutes.  Following this, each tube was struck on an absorbent paper and 
excessive liquid dried from the tubes, to remove the excess moisture for 
enhanced precision of the assay. The radioactivity of each tube was then 
measured in a gamma counter (Cobra II Auto Gamma, A. D. P, South Africa) 
for 1 min per tube and the sample antibody binding affinities, calculated from 
insulin standard curve, which was generated by the gamma counter. Figure 
2.6 is the standard curve generated by the gamma-counter. 
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Figure 2.6: Standard curve generated by the gamma-counter 
 
2.9 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM), unless 
otherwise stated. Statistical significance between groups was assessed via a 
2 way-ANOVA, which was followed by a Bonferroni post-hoc test for multiple 
comparisons. p < 0.05 was considered as statistically significant. Statistical 
analysis of data was performed using GraphPad Prism 5. 
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CHAPTER 3 
Results: STZ-induced type 1 diabetes rat model 
 
3. STREPTOZOTOCIN-INDUCED TYPE 1 DIABETES RAT MODEL 
STZ is known to have a broad spectrum of properties [Like and Rossini, 
1976], of which one is its diabetogenic properties. Its diabetogenic property is 
characterized by the selective destruction of pancreatic islet β-cells, which 
ultimately leads to conditions such as insulin deficiency and hyperglycaemia, 
which mimic human type 1 diabetes mellitus. Several species, including the 
mouse, rabbit, monkey and the rat (which is our model of choice for this 
study), are known to be sensitive to the pancreatic β-cell cytotoxic effects of 
STZ [Wu and Huan, 2008]. Figure 3.1 is a summary of the timeline of the 
experiment. 
 
Weight: 230 – 250g 
Injected with buffer 
(control) and STZ 
(diabetic) 
7 DAYS (1 WEEK) 
Blood glucose measured and animals 
divided into separate groups 
After overnight fasting the 
animals were anaesthetized and: 
• Body weight measured 
• Hearts removed for further  
analysis 
• Blood samples collected for 
serum insulin and blood glucose 
determination 
56 DAYS (8 WEEK) DiaviteTM treatment 
 
Figure 3.1: Diagram outlining the time-line of STZ experiment 
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3.1 Characteristics of experimental animals 
A single intra-peritoneal injection of 40 mg/kg of STZ markedly decreased 
body weight (p < 0.0001) and increased blood glucose concentrations (p < 
0.001) when compared to vehicle injected control animals (refer to Table 3). It 
was found that DiaviteTM treatment significantly increased the body weight (p 
< 0.001) and significantly decreased the elevated blood glucose levels of the 
STZ+DiaviteTM animals when compared to the STZ animals (p < 0.05). In this 
study, DiaviteTM treatment elicited no significant effect on the body weight and 
blood glucose levels of the control, non-diabetic animals. Additionally, 
DiaviteTM treatment significantly increased the serum insulin levels of both the 
control+DiaviteTM (p < 0.001) and STZ+DiaviteTM animals (p < 0.001) (refer to 
Table 3).  
 
Table 3: Weight, fasting blood glucose and serum insulin levels of the 
experimental animals after a 40 mg/kg STZ injection 
 
Parameters Control Control+DiaviteTM STZ STZ+DiaviteTM
Weight (g) 285.66 ± 19.45 275.82 ± 13.79 241.14 ± 28.55*** 260.48 ± 31.03**
Blood glucose 
(mmol/L) 
4.83 ± 0.84 4.90 ± 0.82 19.98 ± 1.31** 15.10 ± 3.42* 
Serum insulin 
level (pmol/L) 
328.36 ± 36.74 549.14 ± 73.27** 274.88 ± 31.11 443.09 ± 54.31**
Weight: ***p < 0.0001 STZ vs. control; **p < 0.001 STZ+DiaviteTM vs. STZ  
Blood glucose: **p < 0.001 STZ vs. control; *p < 0.05 STZ+DiaviteTMvs. STZ 
Serum insulin: **p < 0.001 control+DiaviteTM vs. control; STZ+DiaviteTM vs. STZ 
The data are expressed as mean ± SEM; n = 5 - 8 
 
 
 
 66
3.2 Histological analysis 
3.2.1 Ratio of β-cell to α-cell area 
The dose of 40 mg/kg STZ was sufficient to significantly decrease the ratio of 
β-cell to α-cell area (0.91 ± 0.22 vs. 1.63 ± 0.41; p < 0.05) of the STZ versus 
control animals (refer to Figure 3.2). This dose of STZ lead to the partial 
destruction, however, not complete abolishment of the pancreatic β-cell 
reserve. This is an indication of the succsess of the type 1 diabetes model. 
DiaviteTM treatment tended to increase this ratio in both control+DiaviteTM 
versus control (2.46 ± 0.25 vs. 1.63 ± 0.41) and STZ+DiaviteTM versus STZ 
(1.22 ± 0.42 vs. 0.91 ± 0.22).   
 
 
 
 
 
 
 
 
Figure 3.2: Ratio of β-cell to α-cell area. Pancreatic islets were visually 
identified (different stained colours), interactively demarcated and their total 
areas determined, thereafter the α-cell area and β-cell area were identified and 
the areas measured. The ratio of β-cells to α-cells was calculated by dividing 
the total β-cell area by the total α-cell area measured. The complete description 
of this method is described in section 2.7 of Materials and Methods. The data 
are expressed as mean ± SEM.  
*p < 0.05 control vs. STZ; n = 5 – 8 
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3.2.2 β-cell regeneration 
The STZ group had significantly less small β-cells (0 – 2500 µm2) (5.43 ± 
0.97% vs. 15.33 ± 2.40%; p < 0.001), compared to the control group, which 
was expected since STZ causes β-cell destruction. The effects of DiaviteTM as 
a regenerative agent were observed in the STZ+DiaviteTM group. The 
treatment significantly increased the amount of newly formed small β-cells 
(10.83 ± 1.45% vs. 5.43 ± 0.97%; p < 0.01) within the STZ+DiaviteTM group 
compared to the STZ group (refer to Figure 3.3).  
***
**
 
 
 
 
 
 
 
Figure 3.3: Percentage small β-cells (0 – 2500 µm )2 . Pancreatic islets were sized 
using different islet area parameters. The complete description of this method 
is described in section 2.7 of Materials and Methods. The data are expressed 
as mean ± SEM.   
***p < 0.001 control vs. STZ; **p < 0.01 STZ vs. STZ+DiaviteTM; n = 5 – 8 
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CHAPTER 4 
Results: DIO insulin resistant rat model 
 
4. DIO INSULIN RESISTANT RAT MODEL 
The DIO model is a model of hyperphagia induced obesity with the concurrent 
development of insulin resistance. This model has been characterized in our 
laboratory and shown to be physiologically relevant and comparable to the 
human equivalent of insulin resistance as a result of obesity. 
The data presented in section 4.1 represents the different end-points at which 
the experiments were conducted, which is 8, 12 and 16 weeks (refer to 
section 2.2.2.2 of Materials and Methods). This was done in order to 
document the progression of obesity in our rat model with regard to certain 
biometric parameters, in correlation with myocardial damage incurred during 
ischaemia/reperfusion. The results were obtained through (i) retrograde 
perfusion experiments, with the end-point of infarct size determination, (ii) 
isolated cardiomyocyte experiments, with the aim of determining insulin 
sensitivity and (iii) Western blotting, with the aim of determining protein 
expression and/or phosphorylation.  
 
4.1 RETROGRADE PERFUSION 
Following the 8, 12 and 16 week period on the feeding programme the rats 
were anaesthetized, their hearts excised and mounted on a Langendorff 
perfusion apparatus, where after a water-filled latex balloon coupled to a 
pressure transducer was inserted into the left ventricle of the heart and 
changes in developed pressure measured. After an ischaemic incident was 
induced the heart was reperfused and infarct size determined. In sections 
4.1.1, 4.1.2 and 4.1.3 follows the characteristics of the 8, 12 and 16-week 
animals, along with the results of the infarct size measurements. 
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4.1.1 Animals on 8 weeks feeding programme 
4.1.1.1 Characteristics of experimental animals 
After 8 weeks on the feeding programme, rats on the high caloric diet (DIO) 
displayed significantly increased body weight (p < 0.05), compared to their 
age-matched control counterparts (refer to Table 4.1). It was also evident that 
the group on the DIO diet, presented with increased fed insulin levels, when 
compared to their control littermates. It is thus apparent that the first signs of 
metabolic derangements start as early as 8 weeks of high caloric diet 
consumption (refer to table 4.1). 
 
Table 4.1: Characteristics of the experimental animals after 8 weeks on feeding 
programme 
 
 
 
Parameters Control DIO 
Body weight (g) 360.47 ± 11.70 388.54 ± 11.17* 
Serum insulin level 
(pmol/L) 
652.69 ± 68.62 823.54 ± 97.51 
*p < 0.05 control vs. DIO 
The data are expressed as mean ± SEM; n = 8  
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4.1.1.2 Infarct size at 8 weeks 
Isolated hearts of DIO animals, after being on an 8 week high caloric diet, 
presented with a significantly smaller infarcted area (31.05 ± 6.34% of area at 
risk vs. 47.26 ± 4.10% of area at risk; p < 0.05) than control animals, after a 
regional ischaemic insult (refer to Figure 4.1.1).  
 
 
 
 
 
 
 
Figure 4.1.1: Infarct size (% area at risk) of control vs. DIO animals after 8 
weeks on feeding programme. Hearts were stabilized for 30 min, subjected to 
35 min regional ischaemia, followed by 120 min reperfusion, whereafter infarct 
size was determined. The data are expressed as mean ± SEM.   
*p < 0.05 control vs. DIO; n = 8 
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4.1.2 Animals on 12 week feeding programme 
4.1.2.1 Characteristics of experimental animals 
Contrary to expectations, in this group of animals on the 12 week feeding 
programme, there were no significant differences in weight gain between the 
control and DIO animals. However, even without this significant difference in 
weight gain, it was observe that the DIO animals had significantly higher intra-
peritoneal fat mass (p < 0.0001) and a significant increase in serum insulin 
levels (p < 0.001), compared to the control animals (refer to Table 4.2). This is 
an indication that the consumption of a high caloric diet does lead to insulin 
resistance, even in the absence of total body mass increase. DiaviteTM did not 
have any effect on the total body mass or intra-peritoneal fat mass of the 
control+DiaviteTM versus controls and DIO+DiaviteTM versus DIO. However, 
DiaviteTM treatment significantly increased (p < 0.01) the already elevated 
serum insulin levels in the DIO+DiaviteTM group when compared to the DIO 
group (refer to Table 4.2).   
 
Table 4.2: Characteristics of the experimental animals after 12 weeks on 
feeding programme (8 weeks + 4 weeks DiaviteTM treatment) 
 
Parameters Control Control+DiaviteTM DIO DIO+DiaviteTM
Body weight (g) 459.15 ± 15.19 450.02 ± 15.83 457.28 ± 22.23 496.79 ± 16.67 
Intra-peritoneal 
fat (g) 
11.19 ± 0.82 9.96 ± 0.55 17.52 ± 1.07*** 16.11 ± 1.11*** 
Serum insulin 
level (pmol/L) 
581.85 ± 54.80 629.56 ± 116.47 747.70 ± 71.39** 1269.75 ± 172.65* 
Intra-peritoneal fat: ***p < 0.0001 DIO vs. control; DIO+DiaviteTM vs. 
Control+DiaviteTM
Serum insulin: **p < 0.001 DIO vs. control; *p < 0.01 DIO+DiaviteTM vs. DIO 
The data are expressed as mean ± SEM; n = 8 
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4.1.2.2 Infarct size at 12 weeks 
At 12 weeks, the cardiac infarct sizes of the DIO animals tended to be smaller 
(36.00 ± 4.20% area at risk vs. 44.76 ± 3.90% area at risk), compared to the 
control group. It was found that the cardiac infarcts of DiaviteTM treated 
animals in the control+DiaviteTM group, were significantly smaller (32.61 ± 
5.47% area at risk vs. 44.76 ± 3.90% area at risk; p < 0.05) compared to the 
control group (refer to Figure 4.1.2). Thus, DiaviteTM treatment leads to 
cardioprotection amongst control animals at 12 weeks. 
 
* 
 
 
 
 
 
 
Figure 4.1.2: Infarct size (% area at risk) of control vs. DIO (with and without 
DiaviteTM treatment) animals after 12 weeks on feeding programme. Hearts 
were stabilized for 30 min, subjected to 35 min regional ischaemia, followed by 
120 min reperfusion, whereafter infarct size was determined. The data are 
expressed as mean ± SEM.   
*p < 0.05 control vs. control+DiaviteTM; n = 8 
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4.1.3 Animals on 16 week feeding programme 
4.1.3.1 Characteristics of experimental animals 
The DIO group had significantly higher body weights (p < 0.0001), compared 
to their control counterparts, after the 16 week high caloric diet feeding 
programme (refer to Table 4.3). This obese state was also associated with 
significant elevation in intra-peritoneal fat mass (p < 0.0001), blood glucose (p 
< 0.01) as well as serum insulin levels (p < 0.0001). This suggests that our 
animals developed insulin resistance during this 16 week high caloric feeding 
programme. DiaviteTM treatment was found to further increase the body weight 
(p < 0.001) as well as the serum insulin levels in the DIO+DiaviteTM animals (p 
< 0.05), compared to their DIO counterparts (refer to Table 4.3).  
 
Table 4.3: Characteristics of the experimental animals after 16 weeks on 
feeding programme (8 weeks + 8 week DiaviteTM treatment) 
Parameters Control Control+DiaviteTM DIO DIO+DiaviteTM
Body weight (g) 456.47 ± 9.74 445.98 ± 11.21 493.82 ± 17.47*** 519.42 ± 12.74** 
Intra-peritoneal fat 
(g) 
11.60 ± 0.51 10.00 ± 0.43 17.78 ± 1.19 *** 16.05 ± 1.22 
Blood glucose 
(mmol/L) 
5.49 ± 0.15 4.98 ± 0.20 6.76 ± 0.29* 6.05 ± 0.76 
Serum insulin level 
(pmol/L) 
534.90 ± 29.52 
 
 
634.98 ± 83.83 
 
759.92 ± 19.03 *** 1016.6 ± 79.31 *#
Body weight: ***p < 0.0001 DIO vs. control; **p < 0.001 DIO+DiaviteTM vs. DIO 
Intra-peritoneal fat: ***p < 0.0001 DIO vs. control 
Blood glucose: *p < 0.01 DIO vs. control 
Serum insulin: ***p < 0.0001 DIO vs. control; *p < 0.05 DIO+DiaviteTM vs. DIO;   
#p < 0.001 DIO+DiaviteTM vs. control+DiaviteTM
The data are expressed as mean ± SEM; n = 9 
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4.1.3.2 Infarct size at 16 weeks 
No significant difference was observed in infarct size between the control and 
DIO animals, after being on the 16 week feeding programme. DiaviteTM 
treatment did, however, significantly decrease the infarcted area of both the 
control+DiaviteTM compared to control animals (36.78 ± 3.11% area at risk vs. 
45.11 ± 2.67% area at risk.; p < 0.05) and the DIO+DiaviteTM compared to 
DIO animals (36.48 ± 3.18% area at risk vs. 43.08 ± 3.77% area at risk; p < 
0.05) (refer to Figure 4.1.3). Again, this alludes to the cardioprotective effect of 
DiaviteTM treatment. 
 
 
 
 
 
 
 
Figure 4.1.3: Infarct size (% area at risk) of control vs. DIO (with and without 
DiaviteTM treatment) animals after 16 weeks on feeding programme. Hearts 
were stabilized for 30 min, subjected to 35 min regional ischaemia, followed by 
120 min reperfusion, whereafter infarct size was determined. The data are 
expressed as mean ± SEM. 
*p < 0.05 control vs. control+DiaviteTM; DIO vs. DiaviteTM; n = 9 
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4.2 ISOLATED CARDIOMYOCYTES 
In this model, cardiomyocytes were prepared from hearts of animals on the 
16-week feeding programme (as described in section 2.5 of Materials and 
Methods). This was done in order to determine the insulin sensitivity of these 
cardiomyocytes. This is routinely accomplished in our laboratory by means of 
measuring the ability of the cells to accumulate radio-labeled deoxy-glucose 
before and after stimulation with insulin (refer to section 2.6 of Materials and 
Methods).  
 
4.2.1 Basal glucose uptake by cardiomyocytes after 30 min 
At basal levels, no significant differences were found between the insulin 
sensitivity of the cardiomyocytes from the control animals versus 
cardiomyocytes from the DIO animals. However, DiaviteTM treatment did 
significantly increase the amount of deoxy-glucose accumulation by the 
cardiomyocytes (18.33 ± 3.59 pmol DG/mg prot/30min vs. 9.38 ± 0.74 pmol 
DG/mg prot/30min; p < 0.01) prepared from the DIO+DiaviteTM hearts, which 
indicates that DiaviteTM treatment increases basal glucose uptake by the 
cardiomyocytes. In addition, analysis by 2-way ANOVA showed the overall 
effect of DiaviteTM, on basal glucose uptake, to be significant (p < 0.05). 
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Figure 4.2.1: Basal glucose uptake by cardiomyocytes from control vs. DIO 
rats after 30 min. The insulin sensitivity of cardiomyocytes was determined by 
means of measuring the ability of the cells to accumulate radio-labeled deoxy-
glucose. Refer to section 2.6 of Materials and Methods. The data are expressed 
as mean±SEM.   
*p < 0.01 DIO vs. DIO+DiaviteTM;  n = 6 
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4.2.2 Glucose uptake by cells of control animals versus cells of DIO 
animals after insulin stimulation at different concentrations 
 
4.2.2.1 Stimulation with 1 nM (1000 pmol/L) and 10 nM (10000 pmol/L) 
insulin 
After cardiomyocytes were stimulated with insulin at concentrations of 1 nM 
(Figure 4.2.2 A) and 10 nM (Figure 4.2.2 B) respectively, DiaviteTM treatment 
tended to increase deoxy-glucose uptake at both concentrations within the 
DIO group, however the most significant elevation was observed after insulin 
stimulation at a concentration of 100 nM (Figure 4.2.3). 
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Figure 4.2.2: Glucose uptake by cardiomyocytes from control vs. DIO rats after 
stimulation with (A) 1 nM and (B) 10 nM insulin. The insulin sensitivity of 
cardiomyocytes was determined by means of measuring the ability of the cells 
to accumulate radio-labeled deoxy-glucose after insulin stimulation. Refer to 
section 2.6 of Materials and Methods. The data are expressed as mean±SEM.  n 
= 6 
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4.2.2.2 Stimulation with 100 nM (100000 pmol/L) insulin 
After stimulation with 100 nM insulin, no significant difference were observed 
between the insulin sensitivity of cardiomyocytes prepared from control hearts 
versus cardiomyocytes prepared from DIO hearts. However, DiaviteTM 
treatment resulted in significantly higher glucose uptake by cardiomyocytes 
prepared from DIO+DiaviteTM animals (90.09 ± 13.62 pmol DG/mg prot/30min 
vs. 65.13 ± 7.33 pmol DG/mg prot/30min; p < 0.05) compared to their DIO 
counterparts, indicating a higher level of insulin sensitivity (refer to Figure 
4.2.3). In addition, analysis by 2-way ANOVA showed the overall effect of 
DiaviteTM treatment on glucose uptake after 100 nM insulin stimulation, to be 
significant (p < 0.05). 
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Figure 4.2.3: Glucose uptake by cardiomyocytes from control vs. DIO rats after 
stimulation with 100 nM insulin. The insulin sensitivity of cardiomyocytes was 
determined by means of measuring the ability of the cells to accumulate radio-
labeled deoxy-glucose after insulin stimulation. Refer to section 2.6 of 
Materials and Methods. The data are expressed as mean±SEM.    
*p < 0.05 DIO vs. DIO+DiaviteTM;  n = 6 
 
 79
4.3 PROTEIN EXPRESSION DETERMINATION (WESTERN BLOTS) 
In order to understand and explain the enhanced basal glucose uptake and 
improved insulin sensitivity found in cardiomyocytes after DiaviteTM treatment, 
we evaluated the expression and activation of key enzymes in the insulin 
signaling pathway. 
Following the 16-week period on the feeding programme the rats were 
anaesthetized, their hearts excised, freeze-clamped and used for protein 
expression determination by means of Western blotting techniques (refer to 
section 2.4 of Materials and Methods). Our aim was to investigate whether 
DiaviteTM treatment had any effect on the expression and/or activation of 
GLUT1, GLUT4, total IRβ, total and phosphorylated PKB/Akt, total and 
phosphorylated PTEN and total and phosphorylated PI3K p85. 
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4.3.1 Myocardial GLUT1 content 
It is known that in the heart, GLUT1 protein is associated with basal glucose 
uptake [Abel, 2004].  
No significant difference were found in the GLUT1 content between the 
different experimental groups, as shown in Figure 4.3.1.  
 
 GLUT1
β-tubulin
 
 
 
 
 
 
 
Figure 4.3.1: Total protein levels of GLUT1 in hearts from control and DIO 
animals, with and without DiaviteTM treatment. Stripped blots from control and 
DIO hearts were reprobed with an antibody against β-tubulin to confirm equal 
loading of the protein. The inserts are representative bands from the actual 
Western blots. The top band represents GLUT1 and the bottom band 
represents β-tubulin. The data is presented as mean ± SEM. n = 6 
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4.3.2 Myocardial GLUT4 content 
GLUT4 has previously been shown to be the main carrier protein associated 
with insulin stimulated glucose uptake [Watson and Pessin, 2007; Abel, 2004]. 
There was no significant differences in GLUT4 content between the different 
experimental groups (refer to Figure 4.3.2). 
 
β-tubulin
GLUT4 
 
 
 
 
 
 
 
Figure 4.3.2: Total protein levels of GLUT4 in hearts from control and DIO 
animals, with and without DiaviteTM treatment. Stripped blots from control and 
DIO hearts were reprobed with an antibody against β-tubulin to confirm equal 
loading of the protein. The inserts are representative bands from the actual 
Western blots. The top band represents GLUT4 and the bottom band 
represents β-tubulin. The data is presented as mean ± SEM. n = 6 
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4.3.3 Myocardial total IRβ content 
The insulin receptor (IR) is a transmembrane receptor, consisting of two α- 
and two β-subunits and it is activated by insulin binding [Patti and Kahn, 1998; 
Van Obberghen et al., 2001; Hubbard, 1997]. The binding of the IR to its 
downstream proteins eventually leads to the translocation of the glucose 
transporters to the outer membrane of insulin-responsive tissues, which in 
turn leads to increased uptake of glucose from blood into these tissues 
[Huang and Czech, 2007; Watson and Pessin, 2006]. 
The total expression of IRβ content did not differ significantly between the 
experimental groups (refer to Figure 4.3.3). 
 
β-tubulin
IRβ
 
 
 
 
 
 
Figure 4.3.3: Total protein levels of IRβ in hearts from control and DIO animals, 
with and without DiaviteTM treatment. Stripped blots from control and DIO 
hearts were reprobed with an antibody against β-tubulin to confirm equal 
loading of the protein. The inserts are representative bands from the actual 
Western blots. The top band represents IRβ and the bottom band represents β-
tubulin. The data is presented as mean ± SEM. n = 6 
 
 
 83
4.3.4 Myocardial PKB/Akt content 
PKB/Akt is a known mediator of the metabolic effects of insulin and it is 
suggested that activation thereof is involved in processes such as the 
stimulation of glucose transport and anti-apoptotic processes, which are 
initiated by insulin [Duronio, 2008; Baines et al., 1999]. 
Under basal conditions, no significant difference could be found between 
either the total PKB/Akt or the Ser473 phosphorylation of PKB/Akt in our 
experimental groups (refer to Figure 4.3.5 A and B). However, it was found 
that the ratio of phosphorylated vs. total PKB/Akt was significantly reduced in 
the DIO animals (64.88 ± 3.47 AU vs. 99.85 ± 2.08 AU; p < 0.001) compared 
to their control counterparts, thus less total PKB/Akt was phosphorylated in 
this group (refer to Figure 4.3.4 C). Additionally, a significant reduction was 
observed in this ratio when control+DiaviteTM were compared with control 
animals (71.53 ± 6.01 AU vs. 99.85 ± 2.08 AU; p < 0.001).  
 
A. Total PKB/Akt 
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B. Phosphorylation of PKB/Akt 
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Figure 4.3.4: (A) Total, (B) phosphorylated and (C) ratio of phosphorylated vs. 
total levels of PKB/Akt in control and DIO animals, with and without DiaviteTM 
treatment. Stripped blots from control and DIO hearts were reprobed with an 
antibody against β-tubulin to confirm equal loading of the protein. The inserts 
are representative bands from the actual Western blots. Top band represents 
PKB/Akt and bottom band represents β-tubulin. Data presented as mean ± 
SEM.  
**p = 0.001 control vs. DIO; control vs. control+DiaviteTM; n = 6 
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4.3.5 Myocardial PTEN content 
The lipid phosphatase PTEN has been implicated as a negative regulator of 
the PI3K pathway. PTEN dephosphorylates the PI3K product PIP3 to PIP2, 
thereby blocking the cascade of events generated as a consequence of the 
accumulation of secondary messengers in the plasmalemma. PTEN is thus 
thought to be the main downregulator of the survival pathway [Hlobilkova et 
al., 2003; Mocanu and Yellon, 2007].  
There were no differences observed in the expression of PTEN proteiens at 
basal level in the hearts, when DIO animals were compared to control 
animals.  However, total PTEN protein levels were significantly suppressed 
(0.83 ± 0.13 AU vs. 1.32 ± 0.12; p < 0.01) in hearts of the DIO+DiaviteTM 
group, compared to DIO animals (refer to Figure 4.3.5 A). As PTEN is a 
negative regulator of PI3K, suppressed PTEN suggests improved insulin 
signaling.   
The activity of PTEN was evaluated by measuring phosphorylation at the 
Ser380, Thr382 and Thr383 sites. Phosphorylation at these sites is associated 
with inhibition of PTEN activity. No significant differences were found in the 
phosphorylation state between our experimental groups (refer to Figure 4.3.5 
B). However, the calculated ratio of phosphorylated versus total PTEN (Figure 
4.3.5 C) indicated a tendency of more total PTEN protein being 
phosphorylated in the DIO+DiaviteTM group compared to the DIO group. If 
basal phosphorylation of PTEN is upregulated it suggests a decreased PTEN 
activity, which would allow an increased PKB/Akt phosphorylation with the 
resultant increased glucose uptake. 
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A. Total PTEN 
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C. Ratio of phosphorylated versus total PTEN 
 
 
 
 
 
 
Figure 4.3.5: (A) Total, (B) phosphorylated and (C) ratio of phosphorylated vs. 
total levels of PTEN in control and DIO animals, with and without DiaviteTM 
treatment. Stripped blots from control and DIO hearts were reprobed with an 
antibody against β-tubulin to confirm equal loading of the protein. The inserts 
are representative bands from the actual Western blots. The top band 
represents PTEN and the bottom band represents β-tubulin. The data is 
presented as mean ± SEM. 
*p < 0.01 DIO vs. DIO+DiaviteTM; n = 6  
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4.3.6 Myocardial p85 content 
PI3K is a dimer consisting of a catalytic subunit (p110) and a regulatory 
subunit (p85). We evaluated the expression and phosphorylation of the 
regulatory p85 subunit, as phosphorylation of this subunit is associated with 
activation of the enzyme. PI3K is a key mediator of insulin signaling, thus the 
enhanced phosphorylation will indicate enhanced signaling via this pathway 
[Duronio, 2008; Parcellier et al., 2008; Barthwal et al., 2003]. 
No significant differences were observed in the total expression of p85 
between the experimental groups (refer to Figure 4.3.6 A), however when 
measuring the phosphorylated p85, we found that the phosphorylation of p85 
was significantly reduced (0.77 ± 0.12 AU vs. 1.18 ± 0.08 AU; p < 0.0001) in 
the DIO group compared to their control counterparts (refer to Figure 4.3.6B). 
DiaviteTM treatment had no additional effect on p85 activity. This would 
indicate that signaling via PI3K is attenuated in the DIO animal hearts and that 
DiaviteTM treatment could not improve this. 
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B. Phosphorylation of p85 
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Figure 4.3.6: (A) Total, (B) phosphorylated and (C) ratio of phosphorylated vs. 
total levels of p85 in control and DIO animals, with and without DiaviteTM 
treatment. Stripped blots from control and DIO hearts were reprobed with an 
antibody against β-tubulin to confirm equal loading of the protein. The inserts 
are representative bands from the actual Western blots. Top band represents 
p85 and bottom band represents β-tubulin. Data presented as mean ± SEM. 
***p < 0.0001 control vs. DIO; n = 6 
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CHAPTER 5 
Discussion 
 
The prevalence of obesity is rampantly increasing and it has focused attention 
on a worldwide problem [Cannnon and Kumar, 2009; Deitel, 2003; Park et al., 
2005; Ogden et al., 2007]. Obesity is a serious public health issue, growing in 
most countries [WHO, 2006]. Over the past decades, much research has 
been conducted on the pathophysiology of obesity and its associated 
complications, such as insulin resistance and the consequent development of 
type 2 diabetes. 
For many years plants have been used as a principal source of medicine for 
the treatment of various diseases and recently the investigation into plant 
products have increased. DiaviteTM is an herbal product currently marketed as 
a food supplement with blood glucose and blood pressure stabilizing 
properties as well as having the ability to enhance glucose utilization. It is 
manufactured and distributed in South Africa and consists solely of the dried 
and ground pods of the P. glandulosa tree (Honey mesquite). To our 
knowledge, no studies have been conducted on the mechanisms involved in 
the effects of this plant product and thus the active component of DiaviteTM 
has not yet been identified. Not many studies have been conducted on the P. 
glandulosa plant itself and we could find no literature on human studies 
concerning P. glandulosa. However, much research has gone into other 
related species such as P. juliflora [Ali et al., 2004; Nakano et al., 2004]. Thus, 
the mechanisms and effects of this plant and the product manufactured from it 
are still totally unknown, except for anecdotal claims.  
The initial aim of our study was to investigate the claims of anti-diabetic 
properties made by the producing company. In a pilot study conducted in 
2006, it was found that genetically type 2 diabetic rats (Zucker fa/fa), treated 
with DiaviteTM, had decreased fasting glucose levels and an improved IPGTT 
when compared to untreated controls. In addition, cardiomyocytes prepared 
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from these rats, were more insulin sensitive after DiaviteTM treatment. The 
data of this pilot study are not included in this review.  
After the promising results from the pilot study, we set out to further 
investigate the claims of anti-diabetic properties in other animal models as 
well as investigating the possible mechanisms of action of this product. We 
accomplished this aim by utilizing two well recognised animal models, namely 
a (i) STZ type 1 diabetes animal model as well as a (ii) DIO insulin resistant 
animal model [Arison and Fendale, 1967; Junod et al., 1969; Brondum et al., 
2005; Pickavance et al., 1999].  
 
5.1 Streptozotocin-induced type 1 diabetes 
Type 1 diabetes is an auto-immune disease, where the β-cells of the 
pancreas undergo selective destruction. This disease is characterized by 
hyperglycaemia due to the abolishment of insulin-producing β-cells and is 
associated with long-term complications, which includes retinopathy, 
nephropathy, neuropathy and increased risk of cardiovascular disease 
[Gispen and Biessels, 2000; Vardi et al., 2008].  
It has previously been reported that STZ has the ability to produce mild to 
severe types of diabetes according to the dosages used when it is given to 
animals either by a single intra-venous or intra-peritoneal injection [Junod et 
al., 1969]. STZ was initially isolated from Streptomyces achromogenes in 
1960 and is a known diabetogenic agent for several species, including the 
rodent [Like and Rossini, 1976]. It is characterized by the selective destruction 
of pancreatic islet β-cells, hours after STZ injection [Rossini et al., 1977], 
which ultimately leads to conditions such as insulin deficiency and 
hyperglycaemia, mimicking human type 1 diabetes mellitus.  
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5.1.1 Characterization of STZ-induced type 1 diabetes rodent model 
For our first model we set out to develop a type 1 diabetes rat model in which 
the animal still retained a portion of its pancreatic function and not suffer total 
ablation of its β-cell utilization. We successfully accomplished this with a 
single intra-peritoneal injection of STZ at a dose of 40 mg/kg. This 40 mg/kg 
dosage was sufficient in destroying part of the β-cell reserve, which can be 
observed in the control versus STZ groups (refer to Figure 3.2). A significantly 
decreased β-cell to α-cell area ratio is observed between these two groups. In 
addition, fasting blood glucose levels were significantly elevated (refer to 
Table 3) as early as 2 - 3 days post-injection, which was then followed by a 
gradual increase in blood glucose levels over the remaining period of 
experimentation. Within our model a slightly decreased serum insulin level 
(refer to Table 3) was observed, that would be due to the decreased insulin-
producing β-cells (refer to Figure 3.2).  
This STZ-induced type 1 diabetes model is the model we utilized to determine 
DiaviteTM’s effects on blood glucose and serum insulin levels as well as its 
effects on pancreatic β-cells [Akbarzadeh et al., 2007; da Costa and Vianna, 
2008].  
 
5.2 DIO insulin resistance 
In this study we successfully utilized a model of DIO, which is characterized 
by hyperphagia, increased thermogenesis, hyperleptinaemia and mild insulin 
resistance [Pickavance et al., 1999]. This model has been characterized in our 
laboratory and shown to be physiologically relevant and comparable to the 
human equivalent of insulin resistance as a result of obesity [Du Toit et al., 
2005]. In the DIO model, the diet of the adult rats was changed similarly to the 
changes experienced by humans, changing from a more frugal, rural diet to a 
Westernized, fast food diet.  
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5.2.1 Characteristics of DIO insulin resistant rodent model 
Our second animal model was insulin resistance as a result of obesity. Adult 
male Wistar rats were placed on a high caloric diet for 8, 12 or 16 weeks. This 
was done in order to document the progression of obesity in our rat model 
with regard to certain biometric parameters.  
After being on the high caloric diet for 8 weeks the DIO animals gained 
significantly more body weight than controls. However, they did not display 
signs of insulin resistance (refer to Table 4.1), as there was no significant 
difference between the serum insulin levels of the control versus DIO animals. 
After 12 weeks on the high caloric diet the DIO animals in this particular group 
did not present with increased weight gain compared to their controls as 
would be expected (refer to Table 4.1.2). However, there was a significant 
increase in intra-peritoneal fat mass and serum insulin levels (refer to Table 
4.1.2), indicative of insulin resistance. This same occurrence has previously 
been documented by Naderali and colleagues in a paper published in 2001. 
They found that in a group of rodents that were voluntary fed a high caloric 
diet for a period of 12 weeks, there were animals that gained significant 
weight, but that there were also animals that did not gain much weight. 
Nevertheless, even in those animals that did not gain excessive weight, the 
diet significantly increased visceral fat mass and plasma triglyceride levels 
compared to their chow-fed counterparts and that this low weight gain group 
developed central obesity. This indicates that the consumption of a high 
caloric diet can lead to early signs of insulin resistance, even in the absence 
of obesity. Obesity, physical inactivity or genetic predisposition is usually the 
root for the development of insulin resistance, however, it is not always the 
case. It has been reported that it is rather the distribution of fat, whether 
central/visceral or peripheral obesity, that plays a significant role in the 
development of insulin resistance. Insulin resistance can thus occur in the 
absence of obesity [Rosenthal et al., 1983]. Following a 16-week feeding 
program, we successfully generated a model of insulin resistance as a result 
of obesity, which was the model utilized in the cardiomyocyte and protein 
expression determination experiments. These animals had significantly 
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increased weight gain and intra-peritoneal fat mass, which was accompanied 
by elevated glucose levels and hyperinsulinaemia, which are all trademarks of 
insulin resistance (refer to Table 4.1.3).  
 
5.3 Effects of DiaviteTM consumption 
5.3.1 DiaviteTM as a β-cell regenerative agent 
It is well known that the adult β-cell mass is not static, but that it fluctuates in 
response to different physiological conditions, such as insulin resistance and 
type 2 diabetes. This change in β-cell mass accentuates the importance of 
adaptive mechanisms employed by the pancreas [Bonner-Weir, 2000 (b)]. 
Methods, such as pancreatectomy or partial duct ligation, were found to 
initiate these regenerative programmes, which act to replace missing cells 
[Bonner-Weir et al., 2008]. However, the origin of these regenerative β-cells 
remains unclear and is an ongoing debate amongst researchers.  
By utilizing pulse-chase labeling, Dor and colleagues (2004) established that, 
throughout adult life or after partial pancreatectomy, new β-cells arose from 
pre-existing β-cells, rather than from any other cell subtype. Nir and 
colleagues (2007) obtained similar results after the diphtheria-toxin-mediated 
ablation of β-cell mass. They found that treated mice recovered from 
hyperglycaemia through the formation of new β-cells that mainly originated 
from surviving β-cells. However, numerous other studies suggest alternative 
origins for β-cells during pancreas regeneration, thereby encouraging the 
pancreatic stem cell hypothesis [Zulewski et al., 2001; Petropavlovskaia and 
Rosenberg, 2002]. Wang and colleagues (1995) provided initial evidence of 
non-β-cells converting to β-cells. In their study, they found that by provoking a 
regenerative response in rats, through partial duct ligation combined with 
BrdU pulse-chase labeling, proliferation could not fully account for the drastic 
β-cell hyperplasia observed [Wang et al., 1995]. These findings thus suggest 
that multipotent precursors and/or stem cells may contribe to the regenerative 
capability of the pancreatic islets observed in their study. Xu and co-workers 
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(2008) confirmed the hypothesis that precursor cells are involved in the β-cell 
regenerative process. In their study, they found that duct-lining precursor cells 
were responsible for the pancreatic islet regeneration.  
The observation that β-cells can be regenerated by replication of pre-existing 
β-cells or through the conversion of exocrine cells to β-cells opens new 
avenues for diabetes treatment. 
In our study it was found that DiaviteTM treatment tended to increase the β-cell 
to α-cell area ratio in both control+DiaviteTM versus control and STZ+DiaviteTM 
versus STZ (refer to Figure 3.1) groups. Additionally, DiaviteTM treatment 
significantly increased newly formed small β-cells (0 – 2500 µm2) in the 
STZ+DiaviteTM versus STZ group (refer to Figure 3.2). There were no 
significant differences found regarding new small β-cells formation in our 
control+DiaviteTM versus control group. This could be because the control 
group did not undergo β-cell ablation and thus β-cell regeneration would not 
be necessary.  
From this study it is apparent that the consumption of DiaviteTM leads to 
increased β-cells (when comparing β-cell to α-cell area ratio) and DiaviteTM 
treatment increased the formation of small β-cells in the STZ group that 
suffered β-cell ablation (refer to Figure 3.2). The origin of these newly formed 
β-cells, whether it is from pre-existing β-cells or from converted exocrine cells, 
is still unknown and would warrant further investigation. According to Zhou 
and colluegues (2008), a combination of the transcription factors Pdx1, Ngn3 
and MafA is required in the differentiation of endocrine progenitors to 
hormone-producing β-cells [Zhou et al., 2008]. By determining the expression 
of these transcription factors (Pdx1, Ngn3 and MafA) in the pancreata of 
DiaviteTM treated animals it can be determined whether these newly formed 
cells are from transdifferentiated adult pancreatic cells. 
The β-cell regenerative capacity of DiaviteTM treatment leads to increased β-
cell formation with a possible increase in insulin production. This finding is 
deemed as clinically relevant because being able to enlarge the “window” 
 96
period for sufferers of type 1 and most probably type 2 diabetes will lessen β-
cell loss for an extended period. 
 
5.3.2 The effect of DiaviteTM on insulin secretion  
Insulin is the hormone, secreted by the pancreas, which is responsible for 
glucose uptake and transport to the majority of cells. In response to 
hyperglycaemia the β-cells secrete insulin, which in turn stimulates the uptake 
of glucose by peripheral insulin sensitive tissues.  
We observed a significant increase in insulin secretion post-DiaviteTM 
treatment in both the STZ-induced type 1 diabetes and DIO insulin resistant 
rat models. In the STZ-induced type 1 diabetes model, DiaviteTM consumption 
for 8 weeks resulted in significantly increased serum insulin levels in the 
control as well as the STZ animals (refer to Table 3). This significant increase 
in serum insulin levels was not accompanied by a concomitant decrease in 
glucose levels in the control group (refer to Table 3). In the STZ portion of the 
study, DiaviteTM treatment did significantly lower the elevated blood glucose 
levels, however, the glucose levels were still approximately 3-fold higher than 
in the control animals. In the DIO insulin resistant model, after 16 weeks on 
the high caloric diet, DiaviteTM treatment significantly increased the insulin 
levels of the DIO+DiaviteTM animals, without any significant decrease in 
glucose levels. These results suggest that DiaviteTM might induce insulin 
resistance, since the increased insulin levels are not accompanied by a 
significant reduction in glucose levels. However, cardiomyocytes prepared 
from animals from the same model (DIO for 16 weeks) accumulated more 
deoxy-glucose before and after insulin stimulation (refer to Figures 4.2.1 and 
4.2.3) compared to their control counterparts after DiaviteTM treatment. This 
increased insulin sensitivity after DiaviteTM treatment was also observed in the 
pilot study, conducted in 2006 (refer to page XXV). In this model, 
cardiomyocytes prepared from Zucker rats were more insulin sensitive after 
DiaviteTM treatment. Further studies are being conducted to clarify why the 
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significant increase in insulin levels were not accompanied by a significant 
reduction in glucose levels in this rodent model of DIO.  
  
5.3.3 The effect of DiaviteTM on insulin sensitivity  
Obesity has always been linked to insulin resistance or decreased insulin 
sensitivity and the consequent development of type 2 diabetes [DeFronzo, 
1997]. Insulin resistance occurs when there is a defect in insulin action, which 
inevitably leads to hyperinsulinaemia to maintain euglycaemia. Even though 
the precise mechanism of insulin resistance remains unclear, the general 
assumption has always been that insulin resistance is acquired as a result of 
elevated free fatty acids, which is accompanied by hyperglycaemia and 
hyperinsulinaemia [DeFronzo, 1997; DeFronzo and Ferrannini, 1991]. Insulin 
resistance is associated with abnormalities in insulin signal transduction 
[Haring and Mehnert, 1993; Nolan et al., 1994] and glucose transport. Most 
investigators have interpreted the hyperinsulinaemia to represent a 
compensatory response to counteract the impairment in insulin action 
[DeFronzo, 1997; Reaven, 1988].  
Research suggests that more than one molecular defect in the insulin 
signaling pathway can lead to an insulin resistant phenotype [Woods et al., 
2009]. For this reason, we selected and evaluated key proteins that are known 
to be involved in the insulin signaling pathway and that might be affected 
during insulin resistance, namely, GLUT1, GLUT4, total IRβ, total and 
phosphorylated PKB/Akt, total and phosphorylated PTEN and total and 
phsophorylated PI3K p85. We also evaluated the effect DiaviteTM might have 
on the expression and/or phosphorylation of the above mentioned proteins. 
These are but a few of the numerous proteins involved in the insulin-signaling 
cascade. 
Refer back to section 2.2 of the literature review for a brief reminder as to how 
all these proteins fit into the cascade initiated by insulin binding.  
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5.3.3.1 Myocardial GLUT 1 content  
Compared to GLUT4, GLUT1 is the less abundant glucose transporter in the 
heart and it is known to be responsible for basal glucose uptake [Abel, 2004], 
thus glucose transport via this transporter is insulin independent.  
From the literature is not clear how the expression of GLUT1 is altered during 
disease states such as obesity and early insulin resistance, however, it is 
known that GLUT1 expression is augmented during type 2 diabetes. This is 
thought to be, in part, as a result of prolonged exposure to ROS. The 
increased flux of free fatty acids and glucose is associated with increased 
mitochondrial ROS production, which affects transcription of glucose 
transporters [Bloch-Damti and Bashan, 2005]. Our current model is a model of 
early insulin resistance or pre-diabetes and not full-blown type 2 diabetes, as 
indicated by the elevation in glucose levels, but which are still well below the 
classified level of diabetes (> 8 mmol/L) and the elevated insulin levels (refer 
to Table 4.3). 
In view of the elevated basal glucose uptake by the isolated adult 
cardiomyocytes, which was observed in our DiaviteTM treated animals (see 
Figure 4.2.1); we investigated whether GLUT1 expression was upregulated. 
We accomplished this by measuring the total expression of the GLUT1 
protein, by means of Western blotting techniques. Even with a significantly 
elevated basal glucose uptake, we could find no significant difference between 
the control and DIO animals, with or without DiaviteTM treatment (refer to 
Figure 4.3.1).  
Although we did not find GLUT1 to play a significant role in the increased 
basal glucose uptake, it is possible that enhanced expression of other cardiac 
glucose transporters contributed to the observed increase in basal glucose 
uptake. Other glucose transporters and enzymes have been found to 
contribute to glucose uptake by cardiac muscle, such as the expression of 
GLUT8. Although this glucose transporter’s expression in the heart is much 
less than in other tissue such as testes, the high efficiency of this glucose 
transporter suggests that it may play a role in glucose uptake in the heart 
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[Doege et al., 2000]. We did not, however, measure GLUT8 expression in the 
heart.  
In addition, it is also possible that more GLUT4 is situated in the sarcolemma 
[Matsui et al., 2006], resulting in higher basal glucose uptake, as it is known 
that GLUT4 is not only located in intracellular storage compartments, but also 
at the sarcolemma [Zorzano et al., 1997]. However, in this study, translocation 
between the plasma membrane and intracellular stores were not evaluated.  
 
5.3.3.2 Myocardial GLUT4 content  
GLUT4 is the insulin-responsive glucose transporter [Watson and Pessin, 
2007; Abel, 2004] and it is the most abundant glucose transporter in the heart 
of which its translocation to the plasma membrane plays a vital role in the 
uptake of glucose into the cell. Along with GLUT1, GLUT4 is also located at 
the sarcolemma and in intracellular storage compartments [Zorzano et al., 
1997]. Elevated free fatty acids and intracellular lipid, observed during obesity, 
appears to inhibit insulin signaling, leading to a reduction in insulin-stimulated 
muscle glucose transport that may be mediated by a decrease in GLUT4 
translocation [Boden and Shulman, 2002].  
In our model we evaluated total GLUT4 protein expression in the control and 
DIO groups, with and without DiaviteTM and not the GLUT4 that translocates to 
the sarcolemma. We could find no significant differences in total expression of 
GLUT4 between these groups. As it is known that GLUT4 translocates to the 
membrane to facilitate with glucose uptake, DiaviteTM treatment might 
facilitates this translocation process of GLUT4. However, we did not measure 
translocated GLUT4.  
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5.3.3.3 Myocardial insulin receptor β (IRβ) content 
The IR belongs to a large subfamily of receptor tyrosine kinases [Patti and 
Kahn, 1998], consisting of two extracellular α- and two transmembrane β-
subunits. The binding of insulin to the α-subunit induces a rapid 
conformational change, resulting in the autophosphorylation of specific 
tyrosine residues of the intracellular region of the β-subunit through a 
transphosphorylation mechanism [Van Obberghen et al., 2001; Hubbard, 
1997].   
There is not much literature on the total IRβ expression, but more on the 
tyrosine activity of this receptor under pathological conditions, such as obesity 
and insulin resistance [Hotamisligil et al., 1994; Issad et al., 2002; Amer et al., 
1987]. It might be that there is no significant difference between the total 
expression of the IR in obesity and early forms of insulin resistance, compared 
to controls, as we too observed in our study. Via Western blotting techniques 
of whole heart tissue samples, we measured the total IRβ expression 
comparing control with DIO animals, with or without DiaviteTM treatment, but 
could find no significant differences in the total expression of IRβ. DiaviteTM 
treatment did not result in upregulation of myocardial insulin receptors and the 
elevated glucose uptake, which we observed in the isolated cardiomyocytes, 
can therefore not be as the result of a higher level of IR expression.  
Future studies will warrant investigation into the tyrosine kinase activity of the 
receptor. It has been observed that in disease states such as obesity and 
insulin resistance, the insulin receptor (IR) tyrosine kinase activity is defective 
[Hotamisligil et al., 1994]. In these pathological states insulin’s effects on its 
target tissue are markedly reduced and thus insulin resistance is often 
associated with a decrease in the tyrosine kinase activity of the IR, resulting in 
alterations in insulin signaling [Issad et al., 2002]. A study done by Amer and 
colleagues (1987) on obese, insulin resistant and type 2 diabetic males, they 
found that the tyrosine kinase activity of the insulin receptor from all insulin 
resistant groups was 40% less when compared to the activity of lean control 
subjects. This alteration was present in the absence of changes in the level of 
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the insulin receptor or its insulin binding characteristics. For the purpose of our 
study we did not measure the activity of the IR. 
 
5.3.3.4 Myocardial PKB/Akt content 
PKB/Akt is an important downstream kinase of post-insulin-receptor signaling 
and has been reported to be a good reflection of insulin’s activity. PKB/Akt is 
known as a mediator of the metabolic effects of insulin and it is suggested that 
activation thereof is involved in numerous processes, such as the stimulation 
of glucose transport and anti-apoptotic processes (cardioprotection), initiated 
by insulin [Opie, 1998]. PKBβ/Akt2 (one of the PKB/Akt isoforms) knockout 
mice were found to develop severe diabetes. In the absence of PKBβ/Akt2, 
insulin’s action was blocked and the mice were insulin resistant, with 
hyperglycaemia, hyperinsulinaemia and glucose intolerance [Cho et al., 2001]. 
These observations suggest that PKBβ/Akt2 plays a critical role in glucose 
metabolism. In insulin resistance, dysregulation of PKB/Akt activation may 
result in abnormalities in insulin signaling, causing attenuated glucose 
transport response.  
It has been established that the activation of the PI3K/PKB/Akt signaling 
pathway is also essential for protection against ischaemia/reperfusion injury 
[Mocanu and Yellon, 2007; Hausenloy and Yellon, 2004]. We proposed that 
increased PKB/Akt phosphorylation could be responsible for the reduced 
infarct size observed after DiaviteTM treatment when comparing the 
control+DiaviteTM to the control group as well as the DIO+DiaviteTM to the DIO 
group at 16 weeks. However, this was not the case, as we could find no 
significant difference in phosphorylated PKB/Akt (refer to Figure 4.3.4 B). 
There was also no significant differences in total PKB/Akt expression between 
the experimental groups (refer to Figure 4.3.4 A). These results indicate that 
the altered basal levels of PKB/Akt expression or phosphorylation may not 
have played a role in the cardioprotection that resulted in the reduced infarct 
size we observed, after DiaviteTM treatment. Although the ratio of 
phosphorylation versus total PKB/Akt was lower in the DIO group, DiaviteTM 
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treatment did not change this. In this study, we did not measure PKB/Akt 
phosphorylation after insulin stimulation or after ischaemia/reperfusion (as 
was done for infarct size determination) of the heart, both of which may differ 
after DiaviteTM treatment.  
 
5.3.3.5 Myocardial PTEN content 
PTEN has been implicated as a negative regulator of the PI3K pathway 
[Sasaoka et al., 2006; Mocanu and Yellon, 2007; Hlobilkova et al., 2003]. 
PTEN dephosphorylates the PI3K product PIP3, which serves as crucial lipid 
second messenger in various metabolic effects of insulin, to PIP2, thereby 
reducing PKB/Akt activity. PTEN is thus thought to be the main downregulator 
of this survival pathway [Hlobilkova et al., 2003; Mocanu and Yellon, 2007]. 
PTEN is ubiquitously present in normal cells and its activity can be 
downregulated by phosphorylation or oxidation. The opinion is that in its 
phosphorylated state, PTEN is inactive [Vazquez et al., 2000]. PTEN can also 
be inactivated through oxidation induced by ROS [Leslie et al., 2003]. This 
seems to be the main process, in the acute setting, that regulates PTEN’s 
activity. Amongst the metabolites that induce transcription of PTEN are PPAR-
γ [Teresi et al., 2006] and the tumor suppressor p53 [Wang et al., 2005]. The 
regulation of PTEN and its activity is complex and is yet not completely 
understood, but from what is known, PTEN seems to be an important “switch” 
in the aim of maintaining cellular homeostasis and normal development. 
In our study, we found that the total expression and activity of PTEN was 
decreased in the DIO+DiaviteTM group when compared to the DIO group (refer 
to Figure 4.3.6 A). Suppressed PTEN suggests alleviation in insulin 
resistance. We found no significant differences in the phosphorylated PTEN 
between these different groups (refer to Figure 4.3.6 B). However, it seems as 
if more of the total PTEN protein is phosphorylated in the DIO+DiaviteTM when 
compared to the DIO group (refer to Figure 4.3.4 C). If basal phosphorylation 
of PTEN is upregulated it suggests a decreased PTEN activity, which would 
allow an increased PKB/Akt phosphorylation with the resultant increased 
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glucose uptake. This result is of clinical importance because PTEN 
phosphorylation leads to the activity of PTEN to be suppressed, which 
consequently indicate an increased activity of PKB/Akt and increased cellular 
insulin sensitivity.  
 
5.3.3.6 Myocardial p85 content 
It is well recognised that PI3K is as an essential signal transduction element in 
most the cellular processes, regulated by insulin [Alessi and Downes, 1998]. 
In addition, PI3K regulates multiple and diverse cellular functions, including 
insulin-stimulated glucose transport and cellular survival. PI3K consists of a 
catalytic subunit, p110 and a regulatory subunit, p85 [Alessi and Downes, 
1998]. The regulatory subunit, p85, interacts with tyrosine-phosphorylated 
motifs via two SH2 domains, finally leading to an increased catalytic activity of 
the PI3K complex [Myers et al., 1992].  
In a study done by Cusi and co-workers (2000) it was found that obese non-
diabetic patients showed reduced stimulation of the PI3K pathway, indicating 
the presence of insulin resistance. Our findings, therefore, corroborate that 
insulin resistance is accompanied by attenuated signaling through PI3K as 
evidenced by suppressed p85 phosphorylation in our DIO group. DiaviteTM 
treatment did not improve this.  
Our laboratory studies have shown that DiaviteTM has an effect on insulin 
sensitivity. We found that in our DIO insulin resistant model, DiaviteTM 
consumption significantly increased glucose uptake by cardiomyocytes, at 
basal levels as well as with insulin stimulation, which is an indication of 
increased insulin sensitivity. DiaviteTM had effectively improved insulin 
sensitivity in DIO cardiomyocytes, however, not in control cardiomyocytes. 
The above results regarding the protein expression, was conducted at basal 
conditions, thus without insulin stimulation, which can be the reason for us not 
observing increased p85 phosphorylation after DiaviteTM treatment. Our 
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results also indicate that neither elevated expression nor enhanced 
phosphorylation of p85 is responsible for the higher basal glucose uptake. 
 
5.3.4 Cardioprotective properties of DiaviteTM in the ischaemic heart 
Obesity has been linked to an increased risk of cardiovascular diseases, due 
to the multitude of risk factors associated with obesity, such as hypertension, 
insulin resistance, diabetes and dyslipidaemia [Reaven 1988, Seidell et al., 
1996; Lopaschuk et al., 2007]. However, not many studies have investigated 
the susceptibility of an insulin resistant myocardium in the absence of 
diabetes to ischaemia/reperfusion injury. The focus is more on the 
susceptibility of a diabetic myocardium to ischaemia/reperfusion injury. 
However, it is likely that hearts from obese, insulin resistant individuals are 
more prone to ischaemia/reperfusion injury compared to non-obese 
individuals. A study done by Yue and colleagues (2005) showed that Zucker 
rats (fa/fa), treated with rosiglitazone, had an improved cardiac insulin 
sensitivity and that this increased insulin sensitivity was accompanied by an 
increased resistance to ischaemia/reperfusion injury.  
In our model, hearts of the DIO animals at 8 and 12 weeks, were less 
susceptible to an ischaemic insult, which was contrary to expectations, as it 
does seem as if metabolic derangements start to occur as early as 8 weeks 
[Huisamen et al., 2007 (unpublished data)]. In this study, done in our 
laboratories by Huisamen and colleagues (2007), the early effects of DIO on 
myocardial function were assessed. They found that 8 weeks animals 
displayed signs of insulin resistance with significantly elevated blood glucose 
and serum insulin levels, as well as an elevation in body weight. This is similar 
to what we observed in the present study. In addition, their obese animals 
showed significantly elevated plasma triglycerides, phospholipids and lipid 
peroxidation levels. This observation was also accompanied by a significant 
decrease in aortic output recovery after global ischaemia. It would seem 
logical that the infarct size would be greater in the DIO animals compared to 
their controls, as obesity does not occur in isolation from other metabolic 
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disorders that cumulatively lead to cardiac dysfunction. This is however not 
the case in our study, the study by Huisamen and colleagues (2007), Thim 
and colleagues (2006) and Kristiansen and colleagues (2004) all experienced 
the same unexpected occurrence. There is currently no known evidence as to 
what causes this. 
We also found that DiaviteTM treatment significantly decreased the infarct size 
in our 16 week DIO as well as control animals (refer to Figure 4.1.3). It might 
be that DiaviteTM has an effect on proteins such as PKB/Akt and PI3K, which 
are known to be activated through the pro-survival pathway [Duronio, 2008; 
Baines et al., 1999]. Acute activation of the serine-threonine kinase PKB/Akt is 
cardioprotective and increases glucose uptake, at least in part, through 
enhanced expression of GLUT4 [Matsui et al., 2006]. The pathway that 
involves PI3K and PKB/Akt appears to both negatively regulate factors that 
promote the expression of death genes and positively regulate factors that 
induce survival [Duronio, 2008; Parcellier et al., 2008]. Thus, DiaviteTM might 
induce expression of anti-apoptotic factors, such as Bcl-2 while suppressing 
expression of pro-apoptotic factors, such as caspase-9. However, this was not 
investigated in our study and warrants further investigation. Another possibility 
for the observed cardioprotection in our study might be the increased serum 
insulin levels observed in both our models. DiaviteTM treatment lead to 
increased β-cell formation, which was the reason for the increased serum 
insulin levels we observed and this increased insulin might be the reason for 
the increased protection observed, as insulin itself is a mitogen and is known 
to promote cell survival [Ryu et al., 1999]. 
 
5.4 Adverse effects of DiaviteTM consumption 
In the absence of published data on this plant product, there is also not much 
known about the adverse effects. A standard toxicology study was conducted 
at the primate unit of the MRC (Cape Town) under the supervision of Dr. 
Jurgen Seier, to determine the side effects, if any, of over-consumption of this 
product. It was found that after treating Vervet monkeys with a 1x, 5x and 25x 
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therapeutic dose, no clinically relevant changes were observed. In addition, 
the monkeys did not show signs of hypoglycaemia at any stage over the 3 
month experimental period. Data were compiled in a 100-page document, 
which is available on request. This data is not shown, as the report received 
on the results obtained was too lengthy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107
CHAPTER 6 
Conclusion and future research 
 
The present study has shown that DiaviteTM, which is the trade name of the 
product produced from the pods of the P. Glandulosa tree, modestly lowers 
fasting blood glucose levels, stimulates insulin secretion and leads to the 
formation of small β-cells in rat models. In addition, this study has shown that 
orally consumed DiaviteTM elicits cardioprotection, by protecting the heart after 
an ischaemic incident, as seen through the presence of decreased infarct 
sizes. It was also evident that DiaviteTM treatment could improve glucose 
uptake by isolated cardiomyocytes, which is an indication of improved insulin 
sensitivity. Furthermore, it has been established that DiaviteTM treatment has 
no obvious detrimental effects in either of our rat models and no short-term 
toxic effects or hypoglycaemia over a 3 month period in Vervet monkeys (data 
not shown). 
 
Future research 
To our knowledge, no studies have been conducted on the mechanisms 
involved in the effects of this plant product and thus the active component of 
DiaviteTM has not yet been identified. Due to the multitude of promising 
results, such as the modest lowering of glucose levels, increased insulin 
stimulation, decreased infarct size (after an ischaemic incident), increased 
insulin sensitivity and β-cell regenerative capacity, observed with DiaviteTM 
consumption, it might be feasible to identify and extract the active 
component(s) and package it in the form of capsules instead of the raw plant 
material. As mentioned, DiaviteTM consumption elicits multiple effects in our 
animal models, thus isolating the active components can help determine 
whether the effects observed are as a result of one active substance or as a 
combination of many. 
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We suspect that the decreased infarct size observed in the DIO insulin 
resistant model could be due to the cardioprotective mechanisms, which are 
initiated after insulin binding. Thus, we assume the altered 
expression/activation of signaling molecules known to be involved in the 
insulin signaling pathway are responsible for the cardioprotection we observed 
in our rodent model. Therefore, by perfusing the hearts, as explained in 
section 2.3.1 of Materials and Methods, and determining the protein 
expression the signaling molecules involved in the mechanism of cardiac 
protection can be determined. We can also utilize an insulin-receptor-
knockout model and determine infarct size, similar to our DIO insulin resistant 
model. With this model we will be able to evaluate whether the observed 
decreased infarct size are indeed via mechanisms pertaining to the insulin 
signaling pathway. To investigate this hypothesis we will utilize the 
cardiomyocyte-selective insulin receptor knockout (CIRKO) mice, which are 
obtainable from the laboratories of Prof Dale Abel (University of Utah, Salt 
Lake City, USA) for our analysis. 
Another avenue to be explored is the regenerative capacity of DiaviteTM. From 
our analysis it is not clear what the origin of these small β-cells are and why 
DiaviteTM treatment increases the amount of β-cell formation. Thus, for future 
research, it might be feasible to determine the expression of certain 
transcription factors, such as Ngn3, MafA and Pdx1 in pancreata from 
DiaviteTM treated animals. We can also investigate the origin of these small β-
cells, which might provide a better understanding as to what the role of 
DiaviteTM is in this situation. 
 
Thus, given the current evidence, it seems as if DiaviteTM, after short-term 
use, is beneficial on multiple levels as a dietary supplement in both type 1 and 
type 2 diabetes, however further research is necessary.  
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